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ABSTRACT
For many years the number of Clostridium difficile infections (CDI) has steadily risen. This
common cause of antibiotic-associated diarrhea can have variable clinical presentations ranging
from mild diarrhea to severe cases complicated by the development of pseudomembranous
colitis, electrolyte abnormalities, dehydration, sepsis, and even death. The resistant nature of
the spores produced by the bacteria and the emergence of hypervirulent strains have made
treatment challenging. Previous studies have demonstrated clinician non-adherence to CDI
clinical treatment guidelines may result in poor patient outcomes. This evidence-based practice
project was implemented at a 311 bed academic medical center in the Midwest. The project
development, implementation, and evaluation was guided by the Iowa Model Revised:
Evidence-Based Practice to Promote Excellence in Health Care. Pre-post analysis was used to
determine the effect of clinician utilization of an evidence-based CDI treatment order set on
clinical cure rate (resolution of diarrhea and no longer requiring treatment for CDI), 30-day
disease recurrence, and 30-day readmission rates for CDI. Treatment guideline adherence was
35% in pre-implementation group and 48.9% in post-implementation group (p= 0.113).
Guideline adherence did not have a statistically significant effect on recurrence rates (12.3% vs
14.8%, p = 0.425) or clinical cure rates (15.8% vs 23.9%, p = 0.241). The rate of 30-day
readmission was higher among the guideline treatment adherent group (7% vs 1.1%, p =
0.078). However, this finding was not statistically significant. Clinician order set utilization
increased the rate of guideline adherence versus clinicians that did not use the order set in the
post-implementation group (83.3% vs 43.6%, p = 0.096). Although this is a promising result, the
small sample size was not adequate enough to demonstrate statistical significance. Further
studies are needed to determine the impact of clinician treatment guideline adherence on
patient outcomes.
Keywords: Clostridium difficile infection, evidence-based practice, adherence, outcomes
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CHAPTER 1
INTRODUCTION
Clostridium difficile infections (CDI) are costly, potentially fatal, and becoming
increasingly more common in the United States. Nearly half a million people in the United
States were diagnosed with a Clostridium difficile infection in 2011 (Centers for Disease
Control and Prevention, 2015). Approximately 83,000 of those people developed at least one
recurrence of CDI, and 29,000 died within 30 days of the initial diagnosis (CDC, 2015). In 1993,
CDI led to 85,700 hospitalizations in the United States (Agency for Healthcare Research and
Quality, 2012). In 2009, the number increased to an alarming 336,600 hospitalizations (AHRQ,
2012). Over this 16 year period, CDI associated hospitalizations increased nearly four-fold
(AHRQ, 2012). The average cost for a CDI hospital stay in 2009 was $24,400 with an
aggregate cost of $8.2 billion (AHRQ, 2012; Reveles, Lee, Boyd, & Frei, 2014). Hospital stays
that involved CDI as a secondary diagnosis were more than twice as long than those with a
primary diagnosis of CDI (16.0 days versus 6.9 days) and costs were more than three times
higher respectively ($31,500 versus $10,100) (AHRQ, 2012). Patients with CDI hospitalizations
in 2009 were also more severely ill. An estimated 9.1% of all CDI hospital cases were fatal
compared to less than 2% for all other inpatient hospitalizations (AHRQ, 2012). A study in
Canada demonstrated patients with hospital acquired CDI had an increased median length of
stay by six days compared to those who did not acquire the infection during their
hospitalizations (Forster, Taljaard, Oake, Wilson, Roth, van Walraven, 2012).
The increased incidence and cost of CDI has not gone unnoticed by the United States
government healthcare agencies, such as the Centers for Medicare and Medicaid Services
(CMS). Under the Affordable Care Act (ACA), hospitals are incurring financial penalties for
several hospital acquired conditions (HAC), as well as excessive readmissions for certain
conditions. CDI will be added to the HAC measure scoring system for FY 2017 (CMS, 2015). It
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is critical to understand the characteristics of CDI, the associated risks factors, and develop
strategies to treat, prevent and, control this growing potentially life-threatening and costly
infection.
Background
Clostridium difficile is an anaerobic, endospore-forming, gram positive rod-shaped
bacterium found most commonly in soil and other inanimate surfaces, but it can also occur as a
part of the flora of the human gut (Singh, & Kappar, 2010; Rineh, Kelso, Vatansever, Tegos, &
Hamblin, 2014). As a pathogen, C. difficile produces toxin A and B which can result in extensive
microscopic and gross intestinal disease (CDC, 2015). Furthermore, these microorganisms are
particularly likely to be the cause of antibiotic-associated diarrhea (AAD) and can occur in any
individual treated with antibiotics in any setting. C. difficile is easily transmitted between persons
via an oral-fecal route or from an inanimate objects to persons (Rineh et al., 2014). It has been
estimated CDI accounts for one-fourth of AAD which represents approximately three million
cases per year (Rineh et al., 2014). Transmission-based precautions are utilized in healthcare
facilities to reduce the spread of the spores. Unfortunately, donning gloves and gowns may be
seen as cumbersome and time-consuming leading to poor compliance to such precautions in
the clinical setting.
In C. difficile infections, toxins are present in an individual’s colon and manifests as an
inflammatory and/or immune response to the pathogen. Individuals infected with C. difficile may
develop a variety of clinical signs and symptoms ranging from mild diarrhea and abdominal
cramps to severe presentations involving the development of septicemia (CDC, 2015). In
addition, other life-threatening complications may include: toxic megacolon, dehydration,
electrolyte abnormalities, bowel perforation, acute kidney injury, and other forms of organ failure
(CDC, 2015; Rineh et al., 2014). It has been estimated that 2 to 8% of patients with CDI will
develop the potentially life-threatening complication, pseudomembranous colitis (van der Wilden
et al., 2014). Salvage therapies, such as surgical interventions for complicated cases have
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associated with poor outcomes with mortality ranging from 35 to 80% (Surawicz et al., 2013).
However, early operative management of this complication has been associated with improved
survival (Surawicz et al., 2013).
Persons at risk for CDI include those with antibiotic exposure, gastric acid suppressant
use, gastrointestinal surgeries, lengthy stays in healthcare settings, a severe underlying illness,
immunosuppression, and advanced age (CDC, 2015; Barletta, El-Ibiary, Davis, Nguyen, &
Raney, 2013). CDI are generally treated with antibiotics, such as metronidazole and
vancomycin. However, treatment has become more challenging with the emergence of
vancomycin resistance enterococcus (VRE) and the emergence of a more virulent strain of
Clostridium difficile, type B1, North America Pulsed Field type 1 (NAP1), or PCR ribotype also
known as B1/NAP/027 (CDC, 2015; Kenneley, 2014; Louie et al., 2011; Cornely, Crook,
Esposito, Poirier, Somero, & Gorbach, 2012; O’Horo, Jindai, & Safdar, 2014). The strain is
believed to be more virulent than historical strains due to its binary toxin or ability to produce
both toxin A and B (CDC, 2015). Recent successful treatment approaches have also included
fecal microbiota transplantation. Another treatment, fidaxomicin, has also been noted to
decrease disease recurrence compared to vancomycin (Cornely, et. al, 2012; Louie et al., 2011;
Lancaster & Matthews, 2012; Scott, 2013). Due to limited treatment options, emphasis must
also be placed on preventive strategies to reduce CDI. Those efforts include wiser use of
antibiotics, avoidance or cautious use of gastric acid suppressants, utilization of contact and
enteric precautions, hand hygiene with soap and water, using dedicated medical equipment
when possible, and implementation of cleaning and disinfection protocols and policies (CDC,
2015; Surawicz et al., 2013; Cohen et al., 2010).
Impact of Health Policy on CDI. In 2001, the Institute of Medicine (IOM) developed
their landmark report, Crossing the Quality Chasm: A New Health System for the 21st Century,
in order to address the healthcare challenges the United States was and still is facing. The IOM
cited several concerns within the healthcare system that prompted change including:
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inconsistency in care, patient harm, technology advances, failure to translate knowledge into
practice, changing healthcare needs, and lack of organization and coordination (IOM, 2001).
The intent of their publication was to improve the delivery of care by fostering innovation (IOM,
2001). The IOM suggested six aims for improvement, ten rules for redesign, and three
approaches to change. The six aims included care that is 1) safe; 2) effective; 3) patientcentered; 4) timely; 5) efficient; and 6) equitable (IOM, 2001). The ten rules for redesign focused
on the following principles: a continuous healing relationship, customized care based on patient
needs and values, patient as the source of control, knowledge sharing with freely flowing
information, decision making based on evidence, safety, transparency, anticipation of needs,
decreased waste, and cooperation among clinicians (IOM, 2001). The recommended
approaches included redesigning health professional training, modifying health professional
regulations and accreditation, and use a liability system to support change while retaining
accountability (IOM, 2001).
Fifteen years after the release of the IOM recommendations to improve the health
system in the United States, we continue to face challenges in delivering efficient, effective, and
equitable care. In response, the Patient Protection and Affordable Care Act was enacted in
2010 with the intent to provide affordable, quality healthcare to all Americans (U.S. Department
of Health and Human Services, 2015.). Under this law, provisions have continued to be
developed to further improve the quality and efficiency of healthcare delivery. The Hospital
Readmission Reduction Program (HRRP) was added under the Affordable Care Act in 2012
(CMS, 2015). Under this program hospitals can incur financial penalties for excessive
readmissions within 30 days of discharge for specified conditions. Initially those conditions
included: acute myocardial infarction, heart failure, and pneumonia (CMS, 2015). Despite the
attempts to improve health delivery, health expenditures in the United States exceeded $2.9
trillion or $9,255 per capita in 2013 (CDC, 2015). This represented 17.4% of the United States’
gross domestic product (GDP) (CDC, 2015). In 2014, the CMS ruled to expand the HRRP to
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include additional conditions for fiscal year (FY) 2015. Those additional conditions include:
chronic obstructive pulmonary disease (COPD), elective total hip arthroplasty (THA), and total
knee arthroplasty (TKA) (CMS, 2015).
Although CDI is not currently a condition included under HRRP, this will soon change.
Under the ACA, the Hospital Acquired Condition (HAC) Reduction Program was developed in
effort to reduce hospital acquired conditions, such as catheter associated urinary tract infections
(CAUTI) and central line associated bloodstream infections (CLABSI) (Medicare.gov, 2015).
Since FY 2015, the Secretary of the Department of Health and Human Services has been
required to reduce payments to hospitals that perform poorly with regard to HAC prevention
(Medicare.gov, 2015). Starting in 2016, surgical site infections (colon surgery and abdominal
hysterectomy) have been added to HAC measures (Medicare.gov, 2015). In 2017, methicillinresistant Staphylococcus aureus (MRSA) and Clostridium difficile infection (CDI) will also be
added to the quality measures under HAC reimbursement policy (Medicare.gov, 2015). The
addition of CDI to this legislation will present a particular challenge to advanced practice
providers and other clinicians who, despite their best efforts to rapidly identify and treat
individuals with this condition, face an evolving pathogen that is becoming more common, more
dangerous, and more resistant to standard antibiotic treatment.
Statement of Problem
Data from the Literature Supporting the Need for the Project
Despite efforts to improve CDI prevention and treatment strategies, the cases of CDI
have continued to rise over the last decade. CDI discharges accounted for 5.6 per 1,000 in 2001
compared to 11.1 per 1,000 discharges in 2010 (Chopra, Neelakanta, Dombecki, Awali,
Sharma, Kaye, & Patel, 2015). The CDC (2015) reported nearly half a million people in the
United States developed CDI in 2011. Approximately 29,000 patients died within 30 days of the
initial diagnosis of CDI (CDC, 2015). Fifteen thousand of those cases were directly attributed to
CDI (CD, 2015). One study compared CDI readmissions with all-cause readmissions in seven
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tertiary care hospitals and found CDI discharges returned back to the healthcare system nearly
twice as frequently as all-cause discharges (30.1% vs. 14.1%) (Chopra, Neelakanta, Dombecki,
Awali, Sharma, Kaye, & Patel, 2015). Among the CDI readmission group, 22.2% were admitted
for any reason and 7.8% were readmitted with the primary diagnosis of CDI (Chopra,
Neelakanta, Dombecki, Awali, Sharma, Kaye, & Patel, 2015). It was projected that rates of CDI
hospitalizations would continue to increase between 2011 and 2012 from 12.5 per 1,000 nonmaternal, adult discharges to 12.8 per 1,000 (Steriner, Barrett, & Terrel, 2012). The potential
fatal and costly complications associated with CDI and reimbursement reductions for hospital
onset CDI were additional factors supporting the need for the project.
Data from the clinical agency supporting the need for the project. The clinical
agency selected for the evidence-based project has had an increase in the cases of CDI for the
last three consective years. There were 337 cases in 2013, 361 cases in 2014, and 387 cases
in 2015 (Y. Wung, personal communication, January 21, 2016). See Figure 1.1. Recurrent
community onset, recurrent hospital onset, and recurrent community onset-healthcare facility
onset data for 2015 were not available from the clinical agency.
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Figure 1.1 Cases of Clostridium difficile Infections at Clinical Agency
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Purpose of the EBP project
The purpose of this evidence-based practice project was to determine the effect of
clinician adherence to an evidence-based treatment order set for Clostridium difficile infection
(CDI) on clinical cure rate (resolution of diarrhea and no longer requiring treatment for CDI), 30day disease recurrence, and 30-day readmissions for CDI.
Significance of the Project
CDIs have increased an alarming rate over the last decade. Despite efforts directed at
both disease prevention and treatment, they continue to be a significant healthcare challenge.
CDIs have been associated with longer and more costly hospitalizations. Patient clinical courses
may be complicated by electrolyte abnormalities, renal failure, toxic megacolon, septicemia, and
even death. The increased incidence and cost of CDI has not gone unnoticed by government
healthcare agencies, CMS. Under the ACA, hospitals are incurring financial penalties for
hospital acquired conditions. CDI will be added to the HAC measure scoring system for FY
2017. Clinicians and healthcare systems have an opportunity to improve both prevention and
treatment strategies to combat this potentially fatal and costly problem. Incorporation of an
evidence-based order set for CDI may be a promising solution in improving clinician adherence
to treatment guidelines, improving clinical cure rates, and reducing disease recurrence and CDI
30-day readmissions.
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CHAPTER 2
THEORETICAL FRAMEWORK AND REVIEW OF LITERATURE
The theory and evidence-based practice (EBP) model used as the framework to develop
this evidence-based project were the epidemiological triangle and The Iowa Model Revised:
Evidence-Based Practice to Promote Excellence in Health Care, respectively. The
epidemiological triangle provides an understanding of the fundamentals of epidemiology. It is
essential to understand the basic components of the epidemiological triangle to develop
effective strategies to diagnose, treat, control, and prevent CDI. An EBP model, such as the
Iowa Model, offers to guide the user(s) through the process of incorporation of the best
evidence into clinical practice.
Theoretical Framework: The Epidemiological Triangle
Under additions to the ACA, hospitals will begin facing greater financial penalties for
excessive readmission rates and hospital acquired conditions such as CDI. Clinicians and
healthcare systems need to develop effective approaches to prevent excessive readmissions
and hospital acquired conditions to avoid such penalties. Failure to take meaningful action will
inevitably lead to increased complications, mortality, and potential financial devastation that can
effect healthcare system viability. CDI is a growing threat that requires effective prevention and
treatment strategies.
Description of theoretical framework. The epidemiological triangle is the theoretical
framework used to illustrate the interaction of the key components of communicable diseases.
Those components include the infectious agent, the host, and the environment (Bonita,
Beaglehole, & Kjellström, 2006) (see Figure 2.1). The mechanism by which those components
interact and the factors that determine disease and infection development are explained by the
theoretical framework.
The first part of the epidemiological triangle is the infectious agent or a microorganism
that is capable of causing disease or infection. Infection is the state in which an infectious agent

CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE

9

enters the host, develops, multiples, and causes the host to develop an inflammatory response
to the pathogen. The likelihood a microorganism will cause infection within a host is known as
its pathogenicity. The degree of disease severity caused by the pathogen is known as virulence.
Pathogens can be carried through the environment through a variety of reservoirs, including
humans, animals, and inanimate surfaces, which become the source by which the host initially
acquires the pathogen from the environment. In infectious disease epidemiology, a carrier is a
person or animal that has the pathogen, but is clinically asymptomatic. These carriers,
potentially health care providers or visitors, often become important sources of health care
associated infections (Bonita, Beaglehole, & Kjellström, 2006).
The second component of the epidemiological triangle is the environment. This
component includes transmission or the mode in which the agent is transferred to the host.
There two main modes of transmission: direct and indirect. Direct transmission is the immediate
transfer of the infectious agent from an infected host or reservoir to a host. Direct transmission
may include kissing, touching, sexual intercourse, childbirth, medical instrumentation, coughing,
sneezing, blood transfusion, or placental transfer. Indirect transmission is categorized as
vehicle-borne, vector-borne, or airborne. Vehicle-borne transmission may include contaminated
food or water, towels, or equipment. Vector-borne transmission can occur by way of insects or
animals. Airborne transmission (long distances) can occur through dust and droplets. Parenteral
transmission occurs by injection with contaminated needles (Bonita, Beaglehole, & Kjellström,
2006).
The third component of the triangle is the host or the person or animal that is suitable for
the infectious agent to multiple. The points of entry into the host may be the skin, mucous
membranes, the respiratory tract, and gastrointestinal tract. The host response to the infectious
agent may range from clinically asymptomatic to severe illness or death. The environment is a
crucial element to the development of communicable diseases. Several environmental factors
such as sanitation, temperature, air quality and water quality can affect any component of the

CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE

10

epidemiological triangle (Bonita, Beaglehole, & Kjellström, 2006). Hospitals and other health
care facilities provide care for patients with a variety of infectious diseases and various states
immunocompetence, and health care providers and visitors can serve as potential carriers of a
multitude of pathogens that can be transferred to those patients and cause infection. Medical
treatments and devices also pose a risk to patients. Medical devices, such as, indwelling urinary
catheters and central venous catheters are potential portals for infections. Additionally, certain
medications are capable of immunosuppression or disruption of human normal flora.
Appropriate and mindful use of invasive, indwelling medical devices, wise medication
prescribing practices, and utilization of precautions to reduce pathogenic transmission are
fundamental aspects of preventing hospital acquired infections.

Figure 2.1 The Epidemiological Triangle

Application of theoretical framework to EBP project. Clostridium difficile is a sporeforming bacterium that is spread by indirect transmission or more specifically by an oral-fecal
route. Disruption of normal gut microbiota from antibiotic use and direct ingestion of the spores
are the two modes by which CDI develops. Inanimate objects or fomites such as commodes,
faucets, and medical equipment can contain spores on their surface and can be transferred
from the hands of others that have been in contact with contaminated surfaces. Furthermore,
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the spores can persist on inanimate surfaces for more than 12 months and have demonstrated
resistance to many disinfectants (Rineh et al., 2014). A peptidoglycan cortex and several layers
of a protein coating allow the spores to survive in harsh environmental conditions, including
some disinfectant methods (Rineh et al., 2014). Although the pathogenesis of CDI is not fully
understood, certain mechanisms have been identified as key factors in the immune and
inflammatory responses the bacteria elicits from the host.
C. difficile pathogenecity is reliant upon the effect of at least one of two major toxins, A
and B. Although several strains have been identified, about 10 % account for a virulent strain
known as B1/NAP/027. This strain has been noted to produce high levels of both toxins A and B
(Rineh et al., 2014). This characteristic has made development of an effective treatment
challenging. The hypervirulent toxin B has demonstrated broader tropism and cytotoxicity in vivo
and is more hydrophobic at higher pH levels compared to historical strains. These factors permit
a more rapid cell entry and the ability to cause a more severe form of illness (Rineh et al.,
2014). Binary toxins are then capable of triggering microtubule protrusions in the gastrointestinal
epithelial cells and lead to colonization (Rineh et al., 2014). The binary toxins have two main
mechanisms of action. The first mechanism is the enzymatic action of glucosyltransferases that
lead to disruption of the cytoskeleton and tight junctions, cell rounding, detachment from the cell
membrane, and cell death (Rineh et al., 2014). Detachment from the cell membrane in the
intestinal wall causes the formation of a pseudomembrane between the detached layer and the
basement membrane, which becomes the primary site for C. difficile biofilm formation. The
second mechanism involves triggering pro inflammatory mediators and cytokines that causes
injury by disrupting the protective barrier of the intestinal epithelial lining causing cellular death
(Rineh et al., 2014; Peniche et al., 2013; Barriò et al., 2014).
Bile salts have been also identified as one of the important determinants in spore
germination and inhibition (Rineh et al, 2014; Peniche, Savidge, & Dann, 2013; Barriò et al.,
2014). Primary bile salts (i.e. cholate and taurocholate) have been noted to be stimulators of
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spore germination while secondary bile salts (i.e. deoxycholate and chenodeoxycholate) have
been found to inhibit germination and spore growth (Rineh et al, 2014; Peniche, Savidge, &
Dann, 2013).
Collectively these responses initiate fluid accumulation, edema, increased mucosal
permeability, mast cell degradation, epithelial cell death, and changes in neutrophil recruitment
(Barriò et al., 2014). Complications, such as megacolon, electrolyte derangements, and
septicemia can then ensue.
The two main antibiotics used to treat CDI include vancomycin and metronidazole.
Vancomycin, a glycopeptide, inhibits cell wall synthesis. Metronidazole, a nitroimidazole, causes
loss of helical DNA structure by breaking the DNA strand and inhibiting protein synthesis
leading to cell death. Although they can reduce the number of viable C. difficile bacteria, they do
not have the capability to inhibit toxin and spore formation. Eradication of spores in feces has
proven difficult and their presence has been implicated in 20 to 25% of recurrent cases of CDI
after treatment (Rineh et al., 2014). Fidaxomicin, a macrocylic antibiotic, has been noted to
reduce disease recurrence up to 45% (Rineh et al., 2014). The mechanism of action is
bactericidal, as it inhibits protein synthesis and causes cell death. It additionally has minimal
systemic absorption with high fecal concentrations (Lexicomp, 2015). However, current
treatment with fidaxomicin is cost prohibitive (Scott, 2013). Development of novel therapies
aimed directed at spore and toxin development and proliferation is fundamental. Until more
effective treatments are developed, focus on prevention and control strategies will be crucial to
reduce the growing number of CDI cases. Although this EBP project specifically addresses
treatment of CDI it will be used in conjunction with prevention and control measures that are
currently being utilized. Identification of risk factors and minimizing modifiable risks factors will
also prove to be important clinician considerations.
It is crucial to have an understanding of the components of the epidemiological triangle
(the infectious agent, transmission, and the host), as well as their interactions with the

CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE

13

environment. Knowledge of each of these components is necessary in order to develop effective
interventions to prevent, control, and treat infections. Failure to identify the unique
characteristics of each component will inevitably lead to unsuccessful preventive strategies and
treatment interventions. CDI is no exception.
Strengths and limitations of theoretical framework for the EBP project. The strength of
the framework is its simplicity. It provides the user a fundamental understanding of the
components of infection and communicable diseases. Additionally, the concept can be easily
applied to understanding the basic components of a multitude of infectious diseases. The
epidemiological triangle provides a simple framework for understanding the components of C.
difficile pathogenicity, effect on the host, its transmission, and how it replicates.
Despite the clear and concise nature of the epidemiological triangle, it is not specific to
one infection or disease. While this can be a potential strength of the framework, it could also
serve as a limitation as it provides little guidance in terms of understanding the specific
pathogenesis, effective treatments, and potential sequelae of untreated infections. Each
infectious agent, transmission process, host, and environment is unique. Therefore,
interventions directed at the components of the epidemiological triangle need to be specific to
the uniqueness of the infection causing pathogen(s).
EBP Model of Implementation
Under the ACA, hospitals are being held accountable for excessive readmissions and
hospital acquired conditions. Failure of hospital systems to respond appropriately to the
changes under the ACA could potentially lead to financial instability and threaten organizational
viability. In 2017, CDI will be among the hospital acquired conditions for which hospitals will
incur financial penalties. With the rates of CDI more the doubling over the last decade, hospitals
need to begin developing strategies aimed at prevention and treatment. Clinicians need to find,
critique, synthesis, and apply best evidence to current practices in CDI prevention and
treatment. The process continues with implementation of practice changes and evaluation.
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Finding and evaluating research and new evidence is constantly evolving. It is essential to
search, evaluate, and apply best evidence to current practices to provide effective and efficient
care. The Iowa Model Revised: Evidence-Based Practice to Promote Excellence in Health Care
reflects the dynamic nature of healthcare and can be instrumental in incorporation best
evidence into practice (Buckwalter et al., 2015).
Description of the EBP Model and Application to EBP Project
The Iowa Model of Research-Based Practice to Promote Quality Care was developed in
1994 by Linda Titler and colleagues and first implemented at the University of Iowa Hospitals
and Clinics to guide nurses and other healthcare professionals to utilize research findings to
improve patient care (Titler et al., 2001). The initial version was an algorithm based upon
identification of triggers to improve clinical practice through research utilization. Triggers were
categorized as either problem focused or knowledge focused. The problem focused triggers
included risk management data, quality assessment, quality improvement, identification of a
clinical problem, total quality management or continuous quality improvement (Titler et al.,
2001). Knowledge focused triggers included national agencies or national organizational
standards and guidelines, philosophies of care, questions from institutional standards
committee, and new information in the literature. After a trigger was identified the relevant
research was assembled, critiqued, and evaluated for practice. If sufficient research existed,
outcomes to be achieved would be established. A nursing or multidisciplinary practice would be
developed, and implemented as a practice change on a pilot. An evaluation process would
follow examining the outcomes. Modifications to the practice change or intervention were made
if necessary. The change would be implemented into practice if it was deemed appropriate for
adoption. Outcomes would continue to be monitored after adoption into practice. The results
would then be disseminated to patient and family, staff, and fiscal department. The utility of the
original model was well demonstrated as evidenced by the numerous requests for use in
publications, clinical research programs, clinical practice, and academic courses (Titler et al.,
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2001). The authors of the model were also awarded the Sigma Theta Tau International
Research Award in 1997 (Titler et al., 2001). Several helpful components of the model were
noted to be helpful including: the ease of use, decision making points, emphasis on pilot testing,
and evaluation of change (Titler et al., 2001).
Despite the acceptance of the original model, changes in healthcare and user feedback
prompted revisions. The revised model, released in 2001, included the addition of feedback
loops to illustrate the ongoing process of research utilization, new terminology, and more
decision points (Titler et al., 2001). Healthcare system changes, such as incentives for
research-based practice, increased market competiveness, and the need for efficient and cost
effective practices also incited model revisions (Titler et al., 2001). One of the fundamental
changes of the original model was a name change to The Iowa Model of Evidence-Based
Practice to Promote Quality Care. The name change reflected the evolution of utilization of
research based to evidence-based practice (Titler et al., 2001). The term evidence-based
practice was more reflective of nursing practice as it incorporated research based information,
clinical expertise, and patient preferences (Schmidt & Brown, p. 4, 2015). Research refers to the
systematic search for new knowledge. Although research is utilized in the nursing profession, it
does not reflect or include the aspects of clinical expertise and patient preferences. In the
revised model, process improvement data, internal/external benchmarking data, and financial
data were added under the problem focused triggers (Titler et al., 2001). The addition of new
research or other literature was included under knowledge focused triggers (Titler et al., 2001).
Determining if the topic was a priority for the organization was an action step added beneath the
triggers on the algorithm. The first feedback loop was included after this decision point. If the
topic was not deemed an organizational priority then the algorithm directed the user back to the
triggers. If the topic was determined to be a priority then the next action step was to assemble a
team. The team assembles, critiques, and synthesizes relevant research and other literature. If
sufficient research supports a change, the practice change was piloted. This involved selecting
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outcomes to achieve, collecting baseline data, designing evidence-based guidelines,
implementation of the change, evaluation of the process and outcomes, and any necessary
modifications. If sufficient research did not support a change then a feedback loop directed the
user to seek other types of evidence including: case reports, expert opinion, scientific principles,
and theory. An additional choice for this feedback loop was to conduct new research. After
considering other sources of evidence or conducting new research the feedback loop directs the
user to pilot the practice change. After the practice change was piloted, a decision point calls for
the user(s) to determine if the change was appropriate for adoption into practice. If the change
was adopted then monitoring and analysis of structure, process, and outcome data was
conducted. The following action step calls for dissemination then continued back to the
beginning of the algorithm to problem- and knowledge-based triggers. If a change is piloted but
not appropriate to adopt into practice then the feedback loop directs the user to continue to
evaluate the quality of care and new knowledge and then return again to the beginning of the
algorithm. This incorporation of the feedback loops and actions steps reflected the dynamic and
cyclic nature of clinical inquiry, searching for evidence, appraisal and synthesis of evidence, and
the process of piloting a practice change, evaluation, adoption, and dissemination (Titler et al.,
2001).
The model was again revised and renamed The Iowa Model Revised: Evidence-Based
Practice to Promote Excellence in Health Care. The finalized version was under review at the
time of this project (Buckwalter et al., 2015).The first step in the latest revised version is to
identify triggering issues or opportunities. These include: 1) clinical and patient identified issues;
2) organization, state, and national initiatives; 3) data/new evidence; 4) accrediting organization
requirements/regulations; and 5) philosophy of care. The rise in CDI prevalence, evidence of
poor outcomes associated with guideline discordant treatment, and changes in penalties for
hospital acquired conditions were the triggering issues that prompted this project.
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The second step is to state the question or purpose. For this project, the purpose was to
determine the effect of clinician adherence to an evidence-based order set for CDI treatment on
clinical cure rates, 30-day disease recurrence, and 30-day readmissions for CDI.
The third step or the first decision point is to determine if the topic is a priority. The topic
of CDI treatment and adherence to current guidelines was determined to be an organizational
priority as it would potentially improve clinical cure rates, as well as reduce disease recurrence
and readmissions for CDI. As a result patient outcomes would potentially improve and the
hospital could potentially avoid costly financial penalties for hospital acquired CDI and
readmissions. After several meetings and presentations, a multidisciplinary group of
stakeholders determined the project was an organizational priority. If the topic was not
considered a priority, the feedback loop would direct the user to consider other triggers. Since
the topic was determined to be an organizational priority, the next fourth step was the
development of a team. For this EBP project, the team consisted of a nurse practitioner/nursing
doctoral student, a gastroenterologist, an internist, and clinical pharmacist.
The fifth step was to assemble, appraise, and synthesize the body of evidence. This
involved conducting a systematic search followed by weighing quality, quantity, consistency,
and risk. Since sufficient evidence was identified by the user, a practice change was designed
and piloted as the sixth step in the model. The seventh step was designing and piloting the
practice change and included: 1) engaging patients and verifying preferences; 2) considering
resources, constraints, and approval; 3) developing a localized protocol; 4) creating an
evaluation plan; 5) collecting baseline data; 6) developing and implementing the plan; 7)
preparing clinicians and materials; 8) promoting adoption; and 9) collecting post-pilot data. If
evidence was found to be insufficient, a feedback loop directs the user to conduct research.
In step eight, the user will determine if the change is appropriate for adoption. If it is
deemed inappropriate, then a feedback loop guides the user to consider alternatives, and then
redesign the practice change. If the change is determined to be appropriate, the user will move
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to step nine or integrate or sustain the practice change. This step includes identifying and
engaging key personnel, hardwire change into system, monitor key indicators through quality
improvement, and reinfuse as needed.
The next step is dissemination of the results. After this step the user is directed by a
feedback loop to step one again, identifying trigger issues and opportunities (Buckwalter et al.,
2015).
Strengths and limitations of the Iowa Model for the EBP project. The strengths of
the model include the emphasis of the ongoing, dynamic nature of incorporation of best
evidence into practice, clinical inquiry through identification of problem and knowledge focused
triggers, determination of organizational priorities, evidence appraisal and synthesis, piloting
changes prior to adoption into practice, and dissemination of findings. The revised version of the
model incorporates feedback loops and action steps that reflect the continuum of incorporation
of best evidence into clinical practice. An additional strength of the model is the revisions are
responsive and reflective of current changes in health care.
Limitations of the model may include lack of relevance in an organization or among
individual users that fail to recognize the importance of clinical inquiry and incorporation of best
evidence into practice. The model does not address organizations that may lack financial and
human resources and effective leaders needed to develop multidisciplinary teams to develops
and implement evidence-based practice changes. However, the most recent version in review
now prompts the user to consider resources and constraints.
Literature Search
Identification of Sources Examined for Relevant Evidence
The American College of Gastroenterology (ACG) released an online publication The
Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections in 2013.
The guidelines were developed to provide recommendations for the diagnosis and management
of CDI and prevention and control strategies. The authors considered it as a supplement to the
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2010 Society of Hospital Epidemiologists of America (SHEA)/ Infectious Disease Society of
America (ISDA) and the European Society of Clinical Microbiology and Infectious Diseases
(ESCMID) guidelines and an evidence-based review. In addition to well outlined
recommendations, a summary and strength of recommendations was also provided. The
GRADE system was utilized for evidence appraisal. SHEA/IDSA released a peer reviewed
clinical practice guideline for the diagnosis, management, and prevention of CDI in 2010. The
guideline was developed with the intent to serve as a systematic statement to assist healthcare
providers to make clinical decisions regarding CDI.
Search engines. A search for additional evidence was conducted using the Cumulative
Index to Nursing and Allied Health (CINAHL), ProQuest, The Joanna Briggs Search Institute
(JBI), the Cochrane Library, and Medline/National Center for Biotechnology Information (NCBI).
A librarian from Valparaiso University was consulted and assisted with the evidence search.
Keywords. The keywords included medical subject headings (MeSH terms) in addition
to quotations, Boolean terms, and truncation. The final combination of terms included
“clostridium difficile” AND manage* OR therap* OR guideline* or treat*. For JBI “clostridium
difficile” was used. For the Cochrane Library MeSH term “clostridium difficile” and drug therapy
were used.
Inclusion and exclusion criteria. Inclusion criteria included: 1) publications from 2010
to 2015; 2) adult subjects; 3) publications written in English; and 4) scholarly journals. Exclusion
criteria included: 1) publications prior to 2010; 2) non-adult subjects; 3) animal subjects; 4) nonscholarly or unpublished articles; 5) non-English articles; and 6) duplicate articles.
The search of CINAHL using the above combination of terms, inclusion criteria, and
exclusion criteria yielded 69 articles. The ProQuest database search yielded 66 articles. JBI
yielded 28, Cochrane Library 4 articles, and Medline 28 articles. After hand searching the
results, the following were deemed to relevant, non-duplicate articles: 13 of the 69 CINAHL
articles, 9 or 66 articles from ProQuest, JBI 2 of 28 articles, Cochrane Library 1 of 4 articles, and
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Medline 3 of 28 articles. The final yield of relevant, non-duplicate articles was 21 (see Table
2.1).

Table 2.1
Literature Search Strategies
Database
CINAHL

Search terms

Limiters

Hits

Included

“clostridium
difficile”
AND manage*
OR therap*
OR guideline*
OR treat*
“clostridium
difficile”
AND manage*
OR therap*
OR guideline*
OR treat*
“clostridium
difficile”

2010 to 2015
English
All adults
Scholarly journals

251
251
73
69

8

2010 to 2015
English
All adults
Scholarly journals

133
133
66
66

7

2010 to 2015

28

2

Cochrane

“clostridium
difficile” and
drug therapy

2010 to 2015

4

1

Medline

“clostridium
difficile”
AND manage*
OR therap*
OR guideline*
OR treat*

2010 to 2015
English
Humans
Add adherence
OR readmit*
Clinical journals

4377
1870
1283
1048
206
28

3

ProQuest

JBI

Levels of Evidence and Appraisal of Relevant Evidence
The Melnyk Hierarchy of Evidence (Schmidt & Brown, 2015) was utilized to categorize
the level of evidence. The final 21 articles included 5 systematic reviews (level I), 4 evidencebased practice guidelines (level I), 2 randomized control trials (level II), 1 cohort study (level IV),
3 case control studies (level IV), 2 systematic reviews of descriptive studies (level V), 1
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descriptive study (level VI), 2 interventional studies (level VI), and 1 observational study (level
VI) See Table 2.3.
The articles were appraised using the Critical Appraisal Skills Programme (CASP) which
addresses three categories: validity, results, and usefulness. CASP offers tools specific to
reviews, trials, and case control studies. Each tool offers 10 to 11 questions that address each
of the above categories. Each question has a set of hints that allow the user to answer each
screening question. After reading and critiquing each article, a numeric rating was given to each
appraised article using an adapted version of the CASP tool, (Kline, 2015). With the adapted
version, each screening question has a value of 2 points. A numeric rating of 0 to 7 is poor, 8 to
14 is fair, and 15 to 22 is excellent (Kline, 2015). CASP does not have a specific tool to appraise
clinical guidelines. Therefore, a comprehensive tool from www.evidence-based-medicine.co.uk
was used. The tool was adapted from the St. George’s Health Care Evaluation Unite Appraisal
Instrument for Clinical Guidelines, the Leicestershire Evidence Based Guidelines Checklist, and
the Agency for Health Care Policy and Research Guidelines. The guideline evaluation checklist
is a series of questions that fall under 15 categories that are used to assess validity of clinical
guidelines. The categories include: 1) responsibility for the guideline; 2) objectives; 3) guideline
development group; 4) identification and interpretation of evidence; 5) formulation of
recommendations; 6) likely costs and benefits; 7) peer review; 8) updating; 9) other guidelines;
10) overall assessment of the development process;11) applicability; 12) clarity; 13) guideline
dissemination and implementation 14) national guidelines only and 15) monitoring of
guidelines/clinical audit (www.evidence-based-medicine.co.uk, 2015.). After reading and
critiquing each clinical guideline, a rating of either poor, fair, good, or excellent was assigned
based on utilization of this tool. See Table 2.3 for the literature summary.
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Table 2.2.
Levels of Evidence
Level of Evidence

Type of evidence

Number of articles

I

Systematic reviews
Meta-analysis
EBP guidelines

5 systematic reviews
4 EBP guidelines

II

Randomized control trials

2 randomized control trials

III

Controlled trials without
Randomization

0

IV

Cohort studies or
Case control studies

1 cohort study
3 case control studies

V

Evidence form systematic
reviews of descriptive or
qualitative studies

2 evidence from systematic
reviews of descriptive studies

VI

Evidence from single
descriptive or qualitative
studies

1 descriptive study
2 interventional studies
1 observational study

VII

Evidence from the opinion of
authorities and/or reports of
expert committees

0

Table 2.3
Levels and Appraisal of Relevant Evidence
Citation

Measures

Levels of Evidence

Bagdasarian, Rao, & Malani,
(2015)

Review included: diagnosing,
testing, and treating CDI

Level I
15 excellent

Barletta, El-Ibiary, Davis,
Nguyen, & Raney, (2013)

PPI use and duration and
development
nosocomial CDI

Level IV
18 excellent

Brown & Seifert, (2014)

Complication rates for
patients who received
guideline-concordant therapy

Level IV
18 excellent
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and guideline-discordant
therapy
Cohen et al., (2010)

Strength of recommendLevel I
ations and quality of evidence excellent
was graded using an adapted
tool from the Canadian Task
Force on Periodic Health
Examination

Cornely et. al, (2012)

Clinical cure with fidaxomicin
versus vancomycin

Level II
18 excellent

Jardin, Palmer, Shah, Le,
Beyda, Jiang, & Garey,
(2013)

Use of oral vancomycin for
severe CDI before and after
policy implementation

Level IV
14 fair

Refractory disease in severe
CDI before and after policy
implementation
Jury, Tomas, Kundrapu,
Sitzlar, & Donskey, (2013)

Metronidazole for severe CDI

Level VI
10 fair

Positive test not acted upon
Time from test to positive test
results
Time from positive test to
treatment
Non- adherent treatment
Inappropriate use of empirical
CDI treatment
Khanna, Aronson, Kammer,
Baddour, & Pardi, (2012)

Gastric acid suppression and
disease
severity

Level IV
16 excellent

Khanna & Pardi, (2012)

CDI treatment effectiveness

Level I 14 fair

Lancaster & Matthews,
(2012)

Phase III prospective,
randomized, double-blind,
multicenter study compared
fidaxomicin with oral
vancomycin for the treatment
of mild to moderate CDI
(Louie, et. al)

Level I
16 excellent
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End points- clinical cure
rates, global cure rates, rate
of recurrence and time of
diarrhea resolution

Phase III randomized, noninferiority trial compared
fidaxomicin to oral
vancomycin for CDI
treatment (Crook et. al)
Endpoints- clinical cure, CDI
recurrence, and global cure
Phase III clinical trial
evaluating the role of
concomitant antibiotics with
fidaxomicin compared to oral
vancomycin (Mullane, et. al)
Endpoint- does concomitant
use of antibiotics change
overall clinical outcomes

Louie et. al,
(2011)

Clinical cure rate and global
cure rate

Level II
20 excellent

McEllistrem, McGraw, Sahud, Adherence to clinical
Chan- Tompkins, Goswami,
guidelines for CDI treatment
& Bhanot, (2014)

Level VI
18 excellent

Mulherin, Hutchinson,
Thomas, Hansen, &
Childress, (2014)

Level VI
16 excellent

Concordance of the ATLAS
scoring system with
IDSA/SHEA severity staging
for CDI severity
Sensitivity, specificity,
positive predictive value, and
negative predictive value of
ATLAS scoring system
Clinical characteristics
associated with CDI severity

Nelson et. al, (2011)

Symptomatic cure,
bacteriologic cure, and risk of
relapse

Level I
16 excellent

24
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O’Horo, Jindal, Kunzer, &
Safdar, (2014)

Clinical cure of recurrent CDI

Level I
16 excellent

Ritter & Petri, (2013)

Rate of recurrent CDI

Level V
10 fair

Scott, (2013)

Clinical cure rate, recurrence,
and global cure

Level V
18 excellent

Surawicz et. al, (2013)

GRADE system

Level I
excellent

Van Nispen tot Pannerden,
Verbon, & Kuipers,
(2011)

Treatment options for
recurrent CDI

Level V
12 fair

Xue, (2014)

Efficacy of antibiotic therapy
for CDI

Level I
fair

Xue, (2014)

Efficacy of antimicrobial
therapy for recurrent CDI

Level I
fair

Table 2.3
Levels and Appraisal of Relevant Evidence continued

Purpose/
Aim

Review best
practice
evidence for
diagnosis
and
treatment of
CDI

Sample/
Setting/
Eligibility Criteria
116 articles
Studies related to
CDI diagnosis
and treatment
from 1978 to
2014
Excluded studiesnon English,
animal studies
and studies
including children

Design

Systematic
review

Results/
Findings

Best tests included multiple step
algorithms using PCR or single step
PCR on liquid stool
Multistep- sensitivity 0.68-1.00
specificity
0.92-1.00; Single step-sensitivity
0.94-0.97
Vancomycin and metronidazole are first
line therapies for most patients
Treatment failures have been noted
with metronidazole in severe or
complicated cases
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Clinical success rate for severe CDI
metronidazole 66.3% vancomycin
78.5%
Newer -therapy fidaxomicin is similar to
vancomycin but lower recurrence rates
fidaxomicin 15.4% vancomycin 25.3%
Fecal microbiota transplant response
rates 83-94% for recurrent CDI
Examine the
relationship
between PPI
use and
nosocomial
CDI and
determine if
length of use
increases
risk of CDI

n = 201
(67 with CDI,
134 matched
controls)

Retrospective
case-control

Patients with PPI use were more likely
to develop nosocomial CDI (76% vs
39%; p <.001)
Patients with longer duration of PPI use
was a risk factor for nosocomial CDI
(OR 1.14; 95% CI, 1.02-1.27: p =.018)

Two affiliated
hospitals
Inclusion criteria18 years or older,
LOS of at least 72
hours, acquired
CDI within 48
hours of
admission
Exclusion criteriacommunity
acquired CDI
within 90 days
Matched controlsmet inclusion
and exclusion
criteria,
matched in a 1:2
ratio

Determine if
2010 ISDA
treatment
guideline

n = 180
420 bed tertiary
care referral

Retrospective
case-control

51.7% received guideline concordant
therapy
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concordant
therapy for
CDI reduces
the rates of
complications

county teaching
hospital

Improve the
diagnosis
and
management
of CDI in
adult patients

Literature review
and analysis

Patients receiving guideline concordant
therapy had
fewer complications (17.2% vs. 35.6%,
p = .0007)

Inclusion criteria18 years or older,
treated for CDI
during their
hospital stay

Literature searchPubMed, English
language, 1994 to
2009, terms
“Clostridium
difficile”,
“epidemiology”,
“treatment” and
“infection control”
Reviewed by
SHEA Board of
Directors and
IDSA Standards
and Practice
Committee
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Patients with severe and complicated
CDI received guideline-concordant
therapy less often than patients with
mild disease (19.7% vs. 35.3%, and
81.2% respectively, p <0.001)
Clinical
guideline

Mild to moderate CDI- leukocytosis
15,000 or lower and serum creatinine
less than 1.5 times premorbid level
Severe CDIleukocytosis greater than 15,000 and
serum creatinine equal to or greater
than 1.5 times higher than premorbid
level
Severe, complicated CDIsevere criteria in addition to
hypotension, shock, ileus, or megacolon
Discontinue inciting antimicrobials as
soon as possible (A-II)
Initiate empirical therapy as soon as
severe or complicated CDI is suspected
(C-III)
Avoid use of
anti-peristaltic agents if possible (C-III)
Metronidazole 500 mg tid 10-14 days
for initial mild to moderate CDI (A-I)
Vancomycin 125 mg qid for 10-14 days
for initial severe CDI (B-I)
vancomycin 500 mg qid and per rectum
500 mg in 100 mL normal saline every 6
hours if ileus is present with or without
IV metronidazole 500 mg every 8 hours
for severe, complicated CDI (C-III)
First recurrence mild to moderate CDI,
same regimen as initial episode (A-II)
Do not use metronidazole beyond first
recurrence (C-III)
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Second or third recurrence of CDI, use
pulse dose or tapered vancomycin (BIII)
No recommendations regarding
recurrent CDI in patients who require
continued antimicrobial therapy for
underlying infections (C-III)
Compare the
efficacy and
safety of
fidaxomicin
versus
vancomycin
for the
treatment of
CDI

n = 509 (252
assigned to
fidaxomicin, 257
vancomycin)

Double-blind,
randomized,
non-inferiority
trial

Clinical cure with fidaxomicin versus
vancomycin
(90.6% vs. 97.5% CI -4.3%)
Non inferiority for clinical cure (87.7%
vs 86.8%)

Multicenter in
U.S., Canada,
and Europe

receiving concomitant antibiotics for
other infections cure rate was higher
with fidaxomicin (90.2% vs. 73.3%; p =
0.031)

Inclusion criteriaCDI, 16 years of
age or older, no
more than one
previous episode
of CDI in the 3
months prior

Treatment emergent adverse events
(7.6% vs. 6.5%)

Exclusion criterianegative C.
difficile toxin, <3
bowel
movements in 24
hours,
concomitant
treatment for CDI,
clinical failures,
protocol violation,
cured with < 8
days treatment
Compare
CDI
treatment
patterns and
patient
outcomes
before and
after
Implementation of a
severity-

n = 256
144 before policy
implementation
112 after
implementation
Single tertiary
teaching hospital
Inclusion criteriapositive C. difficile

Cohort study

Use of oral vancomycin for severe CDI
increased significantly following
implementation of the policy 14% (n= 8)
to 91% (n = 48)
Refractory disease in patients with
severe CDI decreased significantly from
37% to 15% following policy
implementation
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policy
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stool toxin, age
18 years of age
or older
Exclusion criteriareceived
antibiotics for CDI
other than metronidazole or
vancomycin,
more than one
recurrence of CDI

Determine if
a CDI
stewardship
initiative
would result
in more
prompt CDI
therapy and
adherence to
treatment
recommendations

Baseline n = 48,
early intervention
n = 52, late
intervention n =
46

Interventional
study

VA center and
adjacent LTCF
Inclusion and
exclusion criteria
not given

Metronidazole prescribed for severe
diseasebaseline vs. early intervention vs. later
intervention
6% vs. 0%
(p =0.03) vs. 0% (p = 1.00)
Positive test not acted upon
5% vs. 0%
(p = .02) vs. 0% (p = .06)
Time from test to positive results
median hours
23 vs. 13
(p = .002) vs. 12 (p = .003)
Time from positive test to treatment
median hours
4 vs. 1
(p = .007) vs. 1 (p = .004)
Non-adherent treatment
dose or duration
8% vs. 0%
(p = .002) vs. 0% (p = .006)
Inappropriate use of empirical CDI
treatment
18% vs. 9%
(p = .07) vs. 2% (p <.0001)

Evaluate the
association
between acid
suppression
and CDI
outcomes

n= 385
county residents
Inclusion criteriaCDI inpatient and
outpatient

Case control
study

36.4% acid suppression (23.4% PPI,
13.5 % H2 blocker, 0.5% both)
Patients taking acid suppression
medications were older (69 vs. 56
years,
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Review
epidemiology,
traditional
and novel
risk factors,
and
advancements in
treatment of
CDI

Review of current
literature
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p = <0.001) and more likely to have
severe disease (34.2% vs. 23.6%, p =
.03) and severe, complicated disease
(4.4% vs. 2.6%, p = .006)
Systematic
review

1991-2002 in Quebec 9.6% CDI
treatment failure rate with
metronidazole then rose to 26% in a
2003-2004 outbreak; Houston study
22% failure rate
Lack of initial response with
metronidazole is associated with
increased mortality
Oral vancomycin is superior to
metronidazole in patients with severe
CDI (cure rate 97% vs. 76%)
Metronidazole is recommended in
patient first or first recurrent CDI.
Change to oral vancomycin if no
improvement in 72-96 hours
Fidaxomicin similar response rates to
oral vancomycin but fewer recurrences
(15.4% vs. 25.3%, p = .005)
Fidaxomicin had lower recurrence rates
in hypervirulent strains compared to oral
vancomycin (7.8% vs. 25.5%, p <.001)
Patients receiving systematic antibiotics
concurrent with CDI treatment had
better cure rate with fidaxomicin
compared to oral vancomycin (90% vs.
79.4%, p = 0.48)
Overall success rate for fecal microbiota
transplant is 92%
No RCTs for recurrent disease
first recurrence in mild to moderate CDI
oral metronidazole for 14 days was
recommended
Second recurrence, 6-7 week tapering
oral vancomycin regimen was
recommended
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Rifaximin, IVIG and vaccines are
alternative treatments
Review
published
literature on
fidaxomicin
for CDI
treatment

Literature search
of MEDLINE,
EMBASE, and
BIOSIS
1975 to 2011
Search termsfidaxomicin,
tiacumicin B,
PAR-101, OPT80, Clostridium,
diarrhea, and
pseudomembranous
colitis.
Additional articles
were obtained
from reference
lists of
publications,
meeting
abstracts, and
correspondence
with the
manufacturer
No grading
method was used
for evidence
appraisal

Systematic
review

Louie et. al
Clinical cure rate 92.1% (fidaxomicin)
vs. 89.9% (vancomycin) (97.5% CI each
arm, -2.6), p value not given
Global cure rate 74.6% (fidaxomicin) vs.
64.1% (vancomycin) (p = 0.006)
Rate of recurrence 15.4% (fidaxomicin)
vs. 25.3% (vancomycin) (95% CI, -16.6
to -2.9; p = 0.005)
Resolution of diarrhea 58 hours
(fidaxomicin) vs. 78 hours (vancomycin)
p value not given
Crook et. al
Clinical cure rate 87.7% (fidaxomicin)
vs. 86.8% (vancomycin) (1 sided 97.5%
CI, -4.9) p value not given
rate of recurrence 12.7% (fidaxomicin)
vs. 26.9% (vancomycin) (97.5% CI, 21.4 to -6.8; p value <0.001)
Global cure rate 76.6% (fidaxomicin) vs.
63.4% (vancomycin) (97.5% CI, 5.220.9; p = 0.001)
Mullane et. al
Clinical cure without concomitant
antibiotics 84.4%% vs. 92.6%% did not
receive a concomitant antibiotic (95%
CI, 3.0%-13.9%; p = <0.001)
Global cure rate without concomitant
antibiotics 74.7% vs. 65.8% (95% CI,
2.54%-15.4%; p = 0.005)
Clinical cure rate with fidaxomicin with
concomitant antibiotics 90.0% vs.
79.4% with vancomycin and
concomitant antibiotics (95% CI, 0.23%20.3%; p -0.004)
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Global cure rate with concomitant
antibiotics 72.7% with fidaxomicin vs.
59.4% with vancomycin (95% CI, 2.1%24.1%, p = 0.02)
Compare
efficacy of
fidaxomicin
vs.
vancomycin
for CDI

n= 548
Multicenter
study

Prospective
double blind,
parallel-group
trial

Clinical cure mITT (modified intent to
treat) 88.2% (fidaxomicin) vs. 85.8%
(vancomycin) (97.5% CI of -3.1%) p
value not given

Inclusion criteria16 years of age
or older, CDI

Rate of recurrence mITT 15.4%
(fidaxomicin) vs. 25.3% (vancomycin)
(95% CI -16.6 to -2.9; p = 0.005)

Exclusion criterialife threatening or
fulminant CDI,
toxic megacolon,
previous
fidaxomicin
exposure, history
of ulcerative
colitis or Crohn’s
disease, more
than one
recurrence of CDI
in 3 months

Rate of recurrence for non virulent
strains C. difficile 7.8% (fidaxomicin) vs.
25.5% (vancomycin) (95% CI, -27.5 to 7.9, p = <0.001)
Rate of recurrence strain B1/NAP/027
24.4% (fidaxomicin) vs. 23.6%
(vancomycin) (p = 0.93)
Global cure mITT 74.6% (fidaxomicin)
vs. 64.1% (vancomycin) (95% CI, 3.1 to
17.7, p = 0.006)
Median time to resolution of diarrhea 58
hours (fidaxomicin) vs. 78 hours
(vancomycin)

Usefulness
of a
computerized decision
support tree
for CDI
treatment

n= 78
661 bed acute
tertiary care
teaching hospital
Inclusion criteriaCDI, nonpregnant, ages
18-89 years,
treatment with
metronidazole,
oral vancomycin
or combination of
metronidazole
and oral
vancomycin
Exclusion criteriahistory of CDI in

Retrospective
observational
study

61.5% of patients received CDI
treatment non adherent to SHEA/IDSA
2010 guidelines for CDI.
For mild to moderate disease, 85.7%
received recommended treatment.
For severe disease, no patients (0/43)
received recommended treatment (p
<0.01). 17.9% of patients received
concurrent oral metronidazole and
vancomycin (not a currently
recommended therapy)

CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE

33

past 1 year,
antibiotics for CDI
< 5 days,
sequential use of
metronidazole
and vancomycin,
receipt of IV
metronidazole or
vancomycin
enemas
Evaluate
concordance
of the ATLAS
scoring
system with
IDSA/
SHEA
severity
staging for
CDI severity

n= 64

Retrospective
study

350 bed
community
hospital

Bivariate analyses showed moderate
agreement between the ATLAS scoring
system and SHEA/IDSA severity
staging for CDI
Sensitivity of ATLAS in predicting CDI
severity 58.3% to 87.5%; specificity
67.5% to 87.5%

Inclusion criteriaCDI, age 19
years of age or
older
Exclusion criteriapregnancy, other
sources of intraabdominal
infection, hypersensitivity to
metronidazole or
vancomycin,
treatment with
oral vancomycin
or oral or IV
metronidazole
within 14 days
prior to CDI
diagnosis

Investigate
the efficacy
of antibiotic
therapy for
CDI, determine the
most
effective
therapy, and
deter-mine
the need for
stopping
causative

15 articles
Literature search
MEDLINE 19662010, EMBASE
1980-2010,
Cochrane Central
Database of
Controlled Trials,
and the
Cochrane IBD
Review Group

Systematic
review

Symptomatic cure
No differences were found among
metronidazole vs. vancomycin
3 studies, N = 335 (79% vs. 71%; CI
95% 0.81-1.03; p = 0.14)
Studies also compared bacitracin vs.
vancomycin; rifaximin vs. vancomycin;
nitazoxanide vs. vancomycin; fusidic
acid vs. vancomycin; teicoplanin vs.
vancomycin
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Specialized Trials
Registry

No statistically significant differences
were found between them

Search terms“pseudomembranous colitis
and randomized
trial”, “Clostridium
difficile and
randomized trial”,
“antibiotic
associated
diarrhea and
randomized trial”

Bacteriologic cure
1 study, n= 59
teicoplanin vs. vancomycin (82% vs.
45%; RR 1.82; 95% CI1.19-2.78; p =
0.006)
Two studies, n= 163
no statistical difference between
metronidazole and vancomycin
(45% vs. 53%; RR 0.85; 95% CI 0.621.17; p = 0.33)
No statistically significant difference
between vancomycin and fusidic acid
Relapse
Two studies, n= 104
no statistically significant differences
were noted between bacitracin and
vancomycin; teicoplanin and
vancomycin; fusidic acid and
vancomycin; nitazoxanide and
vancomycin; metronidazole and
nitazoxanide; metronidazole and
metronidazole plus rifampin;
metronidazole and teicoplanin;
metronidazole and fusidic acid;
teicoplanin and fusidic acid

Review of
literature for
recurrent
CDI
management

64 articles
Literature searchMEDLINE,
CINAHL,
EMBASE, and
the Cochrane
Database
No publication
date or language
restrictions
search terms- not
given

Systematic
review

Vancomycin
10 studies, 6 high quality
Initial cure rate 20-100%, sustained
cure rates 49-100%
pulsing and tapering doses has weak
evidence
Vancomycin with metronidazole
comparator
3 high quality studies
Using sustained response, vancomycin
was as efficacious as metronidazole RR
1.08, 95% CI, 0.85-1.35, p =0.53
Vancomycin with fidaxomicin
comparator
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fidaxomicin appeared slightly more
efficacious
RR 1.86, 95% CI1.04-3.31, p = 0.04
Evidence supporting the use of
vancomycin is moderate, dosing and
duration are variable
Metronidazole
one study concluded metronidazole was
non inferior to vancomycin in first
relapse
two studies favored vancomycin
Review
current
literature for
new
treatment
options for
CDI and
relapse

Literature review

Narrative
review

Metronidazole and vancomycin
Cure rate 90% for metronidazole vs.
98% for vancomycin)
Fidaxomicin and vancomycin
Crook et. al
Clinical cure rate 87.7% (fidaxomicin)
vs. 86.8% (vancomycin) (1 sided 97.5%
CI, -4.9) p value not given
rate of recurrence 12.7% (fidaxomicin)
vs. 26.9% (vancomycin) (97.5% CI, 21.4 to -6.8; p value <0.001)
Global cure rate 76.6% (fidaxomicin) vs.
63.4% (vancomycin) (97.5% CI, 5.220.9; p = 0.001)
Wenisch et al
Oral metronidazole, IV metronidazole,
and vancomycin
IV metronidazole 38.1% mortality, oral
metronidazole 7.4% mortality,
vancomycin 9.5% mortality
30 day mortality IV metronidazole RR
4.3 compared to oral vancomycin (95%
CI 1.92-10, p <0.001)

Use of
fidaxomicin
for CDI

Review of two
RCTs

Review of
RCTs

OPT 80-003 trial
Clinical cure
mITT 88.2% (fidaxomicin) vs. 85.8%
(vancomycin)
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(97.5% CI -3.1)
Recurrence
mITT 15.4% (fidaxomicin) vs. 25.3%
(vancomycin)
Global cure rate
mITT 74.6% (fidaxomicin) vs. 64.1%
(vancomycin)
OPT-80-004 trial
Clinical cure
mITT 87.7% (fidaxomicin) vs. 86.8%
(vancomycin)
Recurrence
mITT 12.7% (fidaxomicin) vs. 26.9%
(vancomycin)
Global cure rate
mITT 76.6% (fidaxomicin) vs. 63.4%
(vancomycin)
Provide
recommendations for
the diagnosis
and
management
of CDI as
well as
prevent-ion
and control
of outbreaks

Literature review

Clinical
guideline

Empiric treatment for suspected CDI
(strong recommendation, moderate
quality evidence)
Discontinue inciting antimicrobial agent
if able (strong recommendation, high
quality evidence)
Mild to moderate CDI metronidazole
500 mg tid for 10-14 days (strong
recommendation, high quality evidence)
Severe CDI vancomycin 125 mg qid for
10 days (conditional recommendation,
moderate quality evidence)
Failure to respond to metronidazole in
5-7 days, consider switching to
vancomycin at standard dosing (strong
recommendation, moderate quality
evidence)mild to moderate CDI in pregnant
women or patients with intolerance to
metronidazole
vancomycin with standard dosing
(strong recommendation, high quality
evidence)
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CDI in patients with segment of colon
not able to be reached by oral
antibiotics (i.e. Hartman’s pouch,
ileostomy)
vancomycin via enema added to above
treatments until condition improves
(conditional recommendation, low
quality evidence)
Avoid or limit use of anti peristaltic
agents (strong recommendation, low
quality evidence)
Severe, complicated CDI without
abdominal distention
vancomycin 125 mg qid plus IV
metronidazole 500 mg every 8 hours
(strong recommendation, low quality
evidence)
Surgical consultation for complicated
CDI (hypotension requiring
vasopressors, sepsis, organ
dysfunction, mental status changes,
white blood cell count >50,000, lactate
equal to greater than 5, failure to
improve with medical therapy after 5
days (strong recommendation,
moderate quality evidence)
First recurrence mild to moderate CDI
same treatment as initial episode
Severe initial recurrence
use vancomycin
Second recurrence
pulsed vancomycin (conditional
recommendation, low quality evidence)
Third recurrence after pulsed
vancomcyin
consider fecal microbiota transplant
(conditional recommendation, moderate
quality evidence)
Treatment
options for
recurrent
CDI

Review of
literature

Narrative
review

First episode mild to moderate CDI
stop antimicrobials if possible,
metronidazole 500 mg tid for 10-14
days or vancomycin 125 mg qid for 10-
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14 days or if unable to take oral
medications IV metronidazole 500 mg
every 8 hours for 10-14 days
consider fidaxomicin 200 mg bid
First episode severe disease
vancomycin 500 mg qid for 10-14 days
or if unable to take oral medication IV
metronidazole 500 mg every 8 hours for
10-14 days and vancomycin 500 mg qid
via nasogastric tube or enema
First recurrence similar to first episode
consider fidaxomicin 200 mg bid or
rifaximin 200-400 mg bid for 10-14 days
Saccharomyces boulardii 500 mg for
21-28 days
Second recurrence mild disease
vancomycin 125 mg qid for 10-14 days
with consider tapering after initial
treatment, fidaxomicin 200 mg bid or
rifaximin 200-400mg for 10-14 days or
Saccharomyces boulardii 500 mg for
21-28 days
Second recurrence, severe disease
Vancomycin 500 mg qid 10-14 days or
if not able to take oral medication then
IV metronidazole 500 every 8 hours
AND vancomycin 500 mg qid via
nasogastric tube or enema
Third or more recurrence
consider fecal microbiota transplant or
monoclonal antibodies or immuneglobulins
Life threatening CDI
surgical consultation and consideration
of colectomy
Best
evidence
regarding
safety and
efficacy of
antibiotic
therapy for
CDI

Literature review

Clinical
guideline

Rate of initial cure
vancomycin vs. metronidazole (79% vs.
66%, p = 0.22)
No difference in mean duration of
diarrhea related to CDI or toxin
clearance
vancomycin vs. metronidazole (2.4 to
3.2 days), (60% vs. 74%, respectively)
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Only one study concluded statistically
significant difference of CDI recurrence
with fidaxomicin and vancomycin (p =
0.05)
No antimicrobial therapy is superior to
others for treatment of initial cure for
mild CDI
Fidaxomicin may cause less recurrence
than vancomycin

Determine
Literature review
the best
evidence
regarding
efficacy and
safety of
anti-microbial
therapy for
recurrent
CDI

Clinical
guideline

First recurrence
same therapy as initial episode
Moderate CDI
metronidazole 500 mg every 8 hours for
10-14 days
Severe CDI
vancomycin 125 mg every 6 hours for
10-14 days
Second recurrence
vancomycin course with taper. 125 mg
every 6 hours for 10-14 days followed
by 125 mg every 12 hours for 7 days,
followed by 125 mg every 24 hours for 7
days, followed by 125 mg every 48-72
hours for 2-8 weeks
Vancomycin as effective as
metronidazole (RR = 1.08, 95% CI,
0.85-1.35, p = 0.53)
Fidaxomicin is slightly more efficacious
than vancomycin (RR 1.86, 95% CI,
1.04-3.31, p = 0.04)
Metronidazole is not recommended for
repeat course given possible
neurotoxicity
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Construct the EBP
Synthesis of Critically Appraised Literature
The appraised literature is described using categories of disease severity and defined as
mild to moderate, severe, severe/complicated, and recurrence. The American College of
Gastroenterology (ACG) defines mild to moderate disease as diarrhea plus any additional signs
or symptoms not meeting severe or severe, complicated criteria (Surawicz et al., 2013). Severe
disease is defined as serum albumin <3gm/dL plus a white blood count of ≥15,000 cell/mm or
abdominal tenderness (Surawicz et al., 2013). Severe, complicated disease is defined as
admission to intensive care unit for CDI, hypotension with or without required use of
vasopressors, fever ≥38.5°C, ileus or significant abdominal distention, mental status changes,
white blood cells ≥ 35,000 cell/mm, serum lactate >2.2 mmol/L, or end organ failure (Surawicz,
et al., 2013). The SHEA/IDSA guidelines define mild to moderate disease as white blood cell
count of 15,000 cells/µL or lower with a serum creatinine level less than 1.5 times the premorbid
level (Cohen et al., 2010). Severe disease is defined as leukocytosis of 15,000 cells/µL or
higher with a serum creatinine level greater than 1.5 times the premorbid level (Cohen et al.,
2010). Severe, complicated disease includes the criteria for severe disease in addition to
hypotension, shock, ileus, or megacolon.
Mild to moderate CDI. The ACG guidelines recommend discontinuation of inciting
antimicrobials, avoiding or limiting use of anti-peristaltic agents if possible for any severity of
CDI, and initiation of empiric therapy until the presence of CDI can be confirmed (Surawiz et al.,
2013). The ACG guidelines recommend metronidazole 500 mg orally three times per day for 10
days (Surawicz et al., 2013). If no clinical improvement is noted within 5 to 7 days, consideration
should be given to changing to vancomycin 125 mg orally four times per day for 10 days. If a
patient is intolerant or allergic to metronidazole or if a woman is pregnant or breastfeeding,
vancomycin with the above standard dosing should be utilized (Surawicz et al.,2013). First
trimester exposure to metronidazole is not recommended as there is concern it can cross the
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placenta. Case reports have described facial anomalies with maternal metronizadole exposures
(Surawicz et al., 2013). Metronidazole and its active metabolites have been found in breast milk
and the plasma of breastfeeding infants (Surawicz et al., 2013).
The SHEA/IDSA offer the same recommendations with exception of the addition giving
metronidazole 500 mg orally three times up 14 days for mild to moderate disease (Cohen et al.,
2010). The ACG guidelines recommend 10 days for the length of treatment for mild to moderate
disease (Surawicz et al., 2013). A systematic review conducted by Bagdasarian et al. (2015)
also recommends metronidazole 500 mg orally three times a day for 10 to 14 days for mild to
moderate CDI. Metronidazole by intravenous route is not recommended as monotherapy
(Bagdasarian et al., 2015). A study by Johnson et al. (2014) showed a lower clinical success
rate for metronidazole versus vancomycin.
A systematic review by O’Horo et al., 2014 found moderate-strength evidence that
treatment with either oral vancomycin or oral metronidazole has consistent efficacy for clinical
cure. A systematic review by Khanna & Pardi (2012) also showed evidence metronidazole has
similar efficacy to vancomycin as a treatment for mild to moderate CDI. A systematic review by
Van Nispen tot Pannerden, C.F., Verbon, A., & Kuipers, E.J. (2011) suggested stopping inciting
antimicrobials, metronidazole 500 mg orally three times per day for 10 to14 days or vancomycin
125 mg orally four times a day for 10 to14 days or metronidazole 500 mg intravenous three
times a day if the oral route could not be given. Consideration to monotherapy with fidaxomicin
200 mg orally twice daily was also suggested.
Severe CDI. The ACG clinical treatment guidelines recommend use of vancomycin 125
mg orally four times per day for 10 days (Surawicz et al., 2013). The SHEA/IDSA guidelines
recommend provide the same recommendation for severe CDI with the course of treatment can
be between 10 and 14 days (Cohen et al., 2010).
A retrospective, non-interventional study by Bass et al., 2012 showed no difference in
clinical cure between monotherapy with oral vancomycin versus combination therapy of oral
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vancomycin with oral metronidazole (57.1% vs.65.1%, p = 0.49). However, the sample size was
small (n =78) and several limitations were noted by the investigators. Those included:
incomplete medical records, potential unaccounted differences in the clinician’s decision to
prescribe monotherapy versus combination therapy, practice changes over the span of the
study, and changed therapy within the first 72 hours (Bass et al. (2013).
In a systematic review by Khanna & Pardi (2012) oral vancomycin was found to be
superior over metronidazole for clinical cure rate in severe CDI (97% vs. 76%). A systematic
review by Bagdasarian et al. (2015) found the same results. An additional study found higher
treatment failure with metronidazole compared to vancomycin (22.4% vs. 14.2%, p = .002).
A systematic review by Van Nispen tot Pannerden et al (2011) suggested vancomycin
500 mg orally four times per day for 10-14 days or metronidazole 500 mg intravenous every 8
hours if oral route is not possible and vancomycin 500 mg four times per day via nasogastric
tube or enema. If patients have a segment of the colon that cannot be reached by oral
medication due an ileus or surgical alteration, consideration should be given to adding
vancomycin enemas to the above therapies (Surawicz et al., 2013).
Severe, complicated CDI. The ACG guidelines recommend vancomycin 125 mg orally
four times per day plus intravenous metronidazole 500 mg three times per day in patients with
severe, complicated CDI without the presence of abdominal distention (Surawicz et al, 2013). In
cases complicated by an ileus or megacolon and/or significant abdominal distention, it is
recommended to use vancomycin 500 mg orally four times per day and per rectum 500 mg in
500 mL of solution four times per time plus intravenous metronidazole 500 mg three times per
day. Surgical consultation for possible colectomy should be considered in patients presenting
with hypotension requiring vasopressors, clinical signs of sepsis, organ dysfunction, mental
status changes, white blood cell count ≥50,000 cell/µL, lactate ≥5 mmol/L, or failure to improve
with medical therapy after 5 days (Surawicz et al., 2013). The SHEA/IDSA guidelines
recommend oral vancomycin 500 mg orally four times per day (and per rectum 500 mg in 100
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mL normal saline every 6 hours if an ileus if present) with or without intravenous metronidazole
500 mg three times per day for severe CDI (Cohen et al., 2010). Additionally, a colectomy is
recommended for severely ill patients. Cases with a serum lactate ≥5 mmol/L and a white blood
cell count ≥50,000 µL have been associated with increased perioperative mortality (Cohen et
al., 2010).
A systematic review by Bagdasarian et al (2015) showed oral vancomycin 125 mg is
non- inferior to higher doses for the treatment of severe CDI. However, expert opinion favors
higher doses in both severe and severe/complicated disease. The review also showed support
for the use of rectal vancomycin as an adjunct therapy. The review also revealed treatment
failures have also been noted in patients that received intravenous metronidazole as
monotherapy (Bagdasarian et al., 2015).
Recurrent CDI. After treatment for an initial episode of CDI, the chance of recurrence is
10 to 20% (McFarland et al., 2009; Surawicz et al., 2013). After one recurrence, the chance of
developing further recurrences is 40 to 60%. The ACG guidelines recommend using the same
regimen as the initial episode for the first recurrence of CDI. However, if the first recurrence is a
severe presentation then vancomycin is recommended. For a second recurrence, a pulsed
vancomycin regimen should be used. Fecal transplantation should also be considered
(Surawicz et al., 2013). The SHEA/ISDA guidelines recommend the same management for
recurrent CDI (Cohen et al., 2010).
A JBI review (Xue, 2014) suggest the following tapering vancomycin regimen: 125 mg
every 6 hours for 10 to14 days, 125 mg every 12 hours for 7 days, 125 mg every 24 hours for 7
days, and 125 mg every 48-72 hours for 2 to 8 weeks. In a systematic review (Bagdasarian et
al., 2015), pulsed vancomycin was recommended for subsequent recurrent CDI as cited in
McFarland et al., (2009). Tapering and pulsed courses of vancomycin were associated with
significantly fewer recurrences (31%; p = .01 and 14.3%; p = .02) (McFarland et al., 2009).
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A systematic review by Van Nispen tot Pannerden et al. (2011) also recommended
repeating the same regimen as the first episode of CDI. For a second recurrence of mild
disease, fidaxomicin or rifaximin or S. boulardii were suggested. However, there is a risk of
fungemia associated with S. boulardii use in patients with central venous catheters and
immunosuppressed patients (Van Nispen tot Pannerden et al., 2011). For a second recurrence
of mild disease, the same systematic review suggested vancomycin 125 mg orally four times
per day for 10 to 14 days followed by tapering, fidaxomicin 200 mg twice daily for 10 to14 days,
or rifaximin 200 to 400 mg twice daily for 10 to14 days, or S. boulardii 500 mg twice daily for 21
to 28 days (Van Nispen tot Pannerden et al., 2011). For a second occurrence with severe
disease, vancomycin 500 mg orally four times per day for 10 to14 days or metronidazole 500
mg intravenous (if oral route is not possible) and vancomycin 500 mg four times per day via
nasogastric tube or enema were recommended according to the systematic review by Van
Nispen tot Pannerden et al (2011). Additionally, consideration to fecal transplant, monoclonal
antibodies, or immunoglobulins were recommended for third and subsequent recurrences (Van
Nispen tot Pannerden et al.,2011).
Duration of therapy. Although it is a common practice to prescribe treatment for 10 to
14 days, the ACG guidelines suggests there is no evidence to support the efficacy of extending
treatment beyond 10 days in mild to moderate cases of CDI (Surawicz et al., 2013). Additionally,
there is also no evidence to support use of extending CDI treatment beyond 10 days for persons
on simultaneous antimicrobial therapy for other infections (Surawicz et al., 2013).
Gastric acid suppression. A case control study by Khanna, Aronson, Kammer,
Baddour, & Pardi (2012) showed patients on gastric acid suppression therapy were significantly
older (69 vs. 56, p <.001), more likely to have severe disease (34.2% vs. 23.6%, p = .03), and
severe, complicated disease (4.4% vs. 2.6%, p =.006) than patients not receiving gastric acid
suppression therapy. There was no association found between treatment failure or recurrent
disease development and gastric acid suppression use. After adjusting for age and co-
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morbidities, patients on gastric suppression therapy were not more likely to experience severe
disease, severe/ complicated disease, treatment failure, or recurrent infection (Khanna et al.,
2012).
A retrospective case control study conducted by Barletta, E-Ibiary, Davis, Nguyen, &
Ramey (2013) showed hospitalized patients who developed CDI were more likely to have been
on a proton pump inhibitor (PPI) (76% vs. 39%; p <.001) and had a longer duration of therapy
(median range 5 days [0-20] vs. 0 days [0-11]; p <.001). A longer duration of PPI therapy was
found to be associated with CDI. In 2012, the Food and Drug Administration’s Adverse
Reporting System released a warning to the public PPI use may increase the risk of Clostridium
difficile associated diarrhea (CDAD). The FDA cited most studies demonstrated a 1.4 to 2.75
higher risk for CDAD for persons using PPIs compared to those that did not use PPIs. However,
many of the subjects had other risks factors including antibiotic use, older age, and co-morbid
conditions (Estes, 2012).
The SHEA/IDSA and ACG guidelines both suggest limiting or avoiding the use of antiperistaltic agents as they may obscure symptoms and trigger the development of complicated
disease. ACG guidelines suggest the use of anti-peristaltic agents in the presence of CDI must
include concomitant CDI treatment (Surawicz et al., 2013).
Fidaxomicin. Fidaxomicin was approved by the FDA for treatment of CDI in 2011. A
treatment specifically for CDI had not been approved by the FDA for nearly twenty years prior to
this approval. Studies have showed promise for its use particularly in regards recurrence rates.
However, cost remains a factor that may be hindering its use. An academic medical center
pharmacist provided the following retail costs for 10 day treatment: vancomycin 125 mg orally
four times a day $1392.00, metronidazole 500 mg orally three times per day $37.84,
and fidaxomicin 200 mg orally twice daily $3,927.12 (T. Shelton, personal communication, June
30, 2015).
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A double blind, randomized control trial RCT comparing the safety and efficacy of
fidaxomicin and vancomycin for the treatment of CDI, which showed non-inferiority of
fidaxomicin for clinical cure rate (87.7% vs.86.8%). In patients receiving antibiotics for other
infections cure rate was higher with fidaxomicin (90.2% vs. 73.3%; p = 0.031). Treatment
emergent adverse events were not significantly different for fidaxomicin and vancomycin (7.6%
vs. 6.5%) (Cornley et al., 2012).
Scott (2013) conducted a review of two RCTs, the OPT 80-003 trial and OPT-80-004
trial. The OPT 80-003 trial revealed a similar clinical cure rate between fidaxomicin and
vancomycin mITT 88.2% vs. 85.8%. Recurrence rate was lower in the fidaxomicin group (mITT
15.4% vs. 25.3%). Global cure rate were also higher among the fidaxomicin group (mITT 74.6%
vs. 64.1%). In the OPT-80-004 trial results were similar compared fidaxomicin and vancomycin
including: clinical cure (mITT 87.7% vs. 86.8%), recurrence (mITT 12.7% vs. 26.9%), and global
cure rate (mITT 76.6% vs. 63.4%).
Another RCT conducted by Louie et al. (2011) also the compared the efficacy of
fidaxomicin and vancomycin in treatment of CDI. The clinical cure rates for fidaxomicin were
non-inferior (mITT 88.2% vs. 85.8% respectively). Significantly fewer patients in the fidaxomicin
group developed recurrence (mITT 15.4% vs. 25.3%, p = 0.005).
The ACG guideline did not include fidaxomicin as a current treatment recommendation.
They did state at the time of its FDA approval for CDI treatment in 2011, only 2 RCTs had
demonstrated non-inferiority to vancomycin. The ACG guideline authors noted several
limitations to these studies including: neither trial was over 90 days, no differences in minimal
inhibitory concentrations (MIC) between B1/NAP/027 and non-B1/NAP/027, both have similar
activity against gram positive stool bacteria, and surveillance testing in the fidaxomicin arm
already had revealed the evolution of a C. difficile strain with elevated MIC concentration to
fidaxomicin due to mutation in the RNA polymerase B. They additionally cite resistance to
vancomycin in vitro has not been observed, and cost of fidaxomicin is significantly higher than
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fidaxomicin. They concluded by advising clinicians should consider fidaxomicin use with caution
until more post marketing clinical trials are conducted (Surawicz et al., 2013).
The 2010 SHEA/ISDA did not include any recommendations regarding the use of
fidaxomicin in CDI. However, it did not receive FDA approval for use in CDI until May 2011.
Guideline concordant treatment and patient outcomes. A study by McEllistrom et al.
(2014) demonstrated of 78 treatment cases in a 661 bed acute tertiary care teaching hospital
examined 78 cases of CDI and the rendered treatment to determine the potential usefulness of
a computerized decision support pathway to guideline CDI treatment. Sixty-one percent of
patients received CDI treatment non adherent to SHEA/IDSA 2010 guidelines for CDI. For mild
to moderate disease, 85.7% received guideline concordant treatment. However, no patients with
severe disease (0/43) received recommended treatment (p <0.01). Nearly 18 % of patients with
severe disease received guideline discordant treatment of concurrent oral metronidazole and
vancomycin.
A study by Jardin et al. (2013) examined the treatment patterns and outcomes for severe
CDI pre- and post- implementation of a severity-based Clostridium difficile infection treatment
policy. Use of oral vancomycin for severe CDI increased significantly following implementation
of the policy (14 % to 91%, p <0.0001), and refractory disease in patients with severe CDI
decreased significantly from 37% to 15% (p = 0.0035) following policy implementation.
Another study by Jury et al. (2013) found a Clostridium difficile stewardship initiative
improved adherence to practice guidelines and improved timeliness of treatment initiation. The
number of patients prescribed metronidazole for severe disease decreased from 6% to 0.
Median time from a positive test to treatment was reduced by 10 hours. 23 vs. 13 (p = .002) vs.
12 (p = .003).
A study by Brown & Seifert (2014) found CDI therapy concordant with the 2010
SHEA/IDSA guidelines had better outcomes. The 51.7% of patients that received guideline
concordant therapy developed fewer complications (17.2% vs. 35.6%, p = .0007). Patients with
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severe and complicated CDI were found to have received guideline-concordant therapy less
often than patients with mild disease (19.7% vs. 35.3%, and 81.2% respectively, p <0.001).
A summation of the CDI pharmacological management recommendations based on
disease severity have been extracted from two major clinical guidelines, the ACG and
SHEA/IDSA. The recommendations include treatment for mild to moderate disease, severe
disease, severe/complicated disease, and recurrent disease. Clinical definitions for each
disease severity are also based on recommendations from those two major clinical guidelines.

Table 2.4
Recommendation for Treatment and Disease Severity Definitions
Disease severity

ACG guidelines

SHEA/IDSA guidelines

mild to moderate disease

mild – presence of diarrhea
only

WBC ≤15,000 OR serum
creatinine < 1.5 times
premorbid level

moderate- diarrhea with
other symptoms not meeting
severe disease criteria
metronidazole 500 mg orally
three times per day for 10
days

metronidazole 500 mg orally
three times per day for 10 to
14 days

if unable to take
metronidazole, vancomycin
125 mg orally four times per
day for 10 days
if no clinical improvement is
noted within 5 to 7 days,
consideration should be
given to changing to
vancomycin 125 mg orally
four times per day for 10
days
severe disease

serum albumin <3 g/dL and
one of the following:
WBC ≥15,000 OR
abdominal tenderness

WBC ≥15,000 OR serum
creatinine >1.5 times
premorbid level
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vancomycin 125 mg orally
four times per day for 10
days
severe/complicated disease

intensive care unit admission
OR
hypotension with or without
required use of vasopressors
OR
fever ≥38.5° OR
ileus OR
megacolon OR
significant abdominal
distention
OR
mental status changes OR
WBC≥35,000 OR
WBC <2,000 OR
serum lactate >2.2 mmol/L
OR
evidence of end organ failure
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vancomycin 125 mg orally
four times per day for 10 to
14 days

hypotension, shock, ileus, or
megacolon
vancomycin 500 mg orally
four times per day AND
metronidazole 500 mg three
times per day AND
rectal instillation of
vancomycin if a complete
ileus is present

vancomycin 500 mg orally
four times per day AND
metronidazole 500 mg
intravenous three times per
day AND
vancomycin 500 mg in 500
mL of saline per rectum four
times per time PLUS
consider surgical
consultation for possible
colectomy
first recurrence, mild to
moderate disease

recurrence- within 8 weeks
of treatment completion

same regimen as initial
treatment

same regimen as initial
treatment
first recurrence, severe
disease

vancomycin 125 mg orally
four times per day for 10
days

vancomycin 125 mg orally
four times per day for 10 to
14 days
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second recurrence

vancomycin 125 mg orally
four times per day for 10
days followed by
125 mg pulsed every 3 days
for ten doses

vancomycin tapered regimen:
125 mg every 6 hours for 1014 days,
125 mg every 12 hours for 7
days,
125 mg every 24 hours for 7
days, and
125 mg every 48-72 for 2 to 8
weeks

≥ 3 recurrences

consider fecal microbiota
transplant

consider fecal transplant OR
consider nitazoxamide OR
intravenous immunoglobulins
150-400 mg/kg

*Discontinuation of inciting antibiotics should be stopped if possible and gastric acid suppression should be stopped
or limited if possible

Answering the Clinical Question
What is the effect of clinician adherence to an evidence-based Clostridium difficile infection
(CDI) order set on clinical cure rate (resolution of diarrhea and no longer requiring treatment for
CDI), 30-day disease recurrence, and 30-day readmission rates for CDI?
The EBP recommendations were based upon the ACG and SHEA/IDSA guidelines and
supplemented with expert opinions. The recommendations drawn from the literature were
utilized to develop a pharmacological evidence-based order set for CDI treatment. See Table
2.5. Although the are several other therapies that have been utilized for the treatment of CDI,
the focus of this project is on pharmacological management supported by the two current major
guidelines from ACG and SHEA/IDSA. Expert opinions from a gastroenterologist, an internist,
and a clinical pharmacist were elicited and incorporated into the order set. Fidaxomicin was not
included in the order set as it is a non-formulary drug at the clinical agency, and current policies
do not allow inclusion of non-formulary drugs on order sets. See appendix A.
The development and implementation provided clinicians with an accessible tool that
defined disease and provided recommended treatment. The primary outcome were to determine
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the effects of clinician adherence to an evidence-based treatment order set on clinical cure rate,
30-day disease recurrence, and 30-day readmissions for CDI.

CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
Hospital systems are currently facing potential financial penalties for hospital acquired
infections, such as catheter associated urinary tract infections (CAUTI) and central line
associated blood stream infections (CLABSI) in order to improve patient outcomes and reduce
healthcare expenditures. In the next few years, CDI will be included in the Center for Medicare
and Medicaid’s HAC Reduction Program. Therefore, it is crucial to implement evidence-based
practices to provide the best care for CDI to achieve clinical cure, reduce the development of
associated complications, and prevent disease recurrence. This is especially important with the
emergence of hypervirulent strains of C. difficile and increased risk for recurrent disease.
Implementation of an evidence-based practice order set for the treatment of CDI can be a
potential solution to improve clinician adherence to current clinical guidelines. Therefore,
improvement in clinical cure rates, reduction in disease recurrence, reduction in readmission
rates for CDI, and prevention of associated complications could potentially be achieved. This
chapter describes the proposed project methods to answer the following the clinical question:
What is effect of clinician adherence to an evidence-based Clostridium difficile infection (CDI)
treatment order set on clinical cure rate (resolution of diarrhea and no longer requiring
treatment), 30-day disease recurrence, and 30-day readmission rates for CDI?
Participants and Setting
Participants in the retrospective pre-implementation phase of this project included a
convenience sample of 100 adult, non-critical care inpatients who met the eligibility criteria at a
Midwestern academic medical center during the 3-month period of time prior to project
implementation (n = 100). The participants in the prospective post-implementation phase
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included a convenience sample of 45 adult, non-critical care inpatients (n = 100). Eligibility
criteria included patients with a stool assay confirmed CDI, age 18 years or older, and inpatient
status in a non-critical care areas. Exclusion criteria included non-English speaking patients,
and persons not able to provide informed consent or consent by proxy.
The academic medical center is part of a large and comprehensive health care system.
The health care system is comprised of 18 hospitals, as well as urgent care centers, and
multiple outpatient facilities throughout a Midwestern state. The combined hospitals have a total
of 3,098 staffed patient beds and 29,395 team members. Six of those hospitals have achieved
and maintained Magnet Designation, a national honorary recognition for nursing excellence
bestowed by the American Nurses Credentialing Center. Fewer than 400 hospitals nationwide
have achieved this highly regarded designation (IU Health, 2015).
The academic medical center is comprised of two not-for-profit hospitals that have a total
of 1,371 beds and combined admit 55,379 patients annually. The facility selected for the EBP
project implementation has a 311 bed capacity. The academic medical center has been
nationally recognized in The U.S. News Best Hospitals for 18 consecutive years. This is a
national ranking achieved by the top 3% of U.S. hospitals. Additionally, the health care system
has a partnership with one of the largest, well known, and prestigious medical schools in the
Midwest (IU Health, 2015).
The mission of the healthcare system is to improve the health of our patients and
community through innovation and excellence in care, education, research and service. The
proposed evidence-based project is congruent to that mission of excellence (IU Health, 2015).
Outcomes
The primary outcome of interest was clinician adherence to an evidence-based
treatment order set for CDI treatment. Secondary outcomes of interest included: achievement of
clinical cure defined as resolution of symptoms and not requiring further treatment for CDI, 30day disease recurrence, and 30-day readmission rates for CDI.
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Intervention and Planning
The CDI treatment order set was based on two national guidelines from ACG and
SHEA/IDSA and supplemented with other high level evidence from RCTs and systematic
reviews. The order set included severity-based pharmacological treatments, as well as clinical
definitions for each disease severity. The disease severities included mild to moderate, severe,
severe/complicated, as well as recurrence. The order set was be reviewed by three health care
professionals (a gastroenterologist, an internist, and a clinical pharmacist) associated with the
healthcare system prior to implementation. The feedback from the reviewers was incorporated
into the order set. The finalized order set was presented to the academic medical center
informatics review board for approval. Prior to implementation, clinicians were provided with
information about the order set using a multimodal educational approach, including: email
notifications, newsletter articles, posters, and face-to-face discussions. It was initially planned
for C. difficile positive stool assays to trigger a computer-based alert and message referring the
clinician to utilize the CDI order set. Due to time restrictions associated with implementing the
project and concern for alert fatigue, this was not feasible. Alert fatigue is a phenomenon that
occurs when healthcare workers’ exposure to numerous alerts, ranging from physiological
monitoring alarms to drug-drug interactions notifications with computerized physician order
entry, can lead to desensitization and failure to respond to such alerts over time. This can
potentially lead to unintended patient harm. Wise utilization of computer-based alerts may help
to minimize such unintentional consequence of clinicians and other healthcare workers ignoring
the alerts (Embi & Leonard, 2012). Clinicians and other healthcare workers at the clinical
agency currently receive computer-based alert for tobacco cessation, infectious disease (i.e.
VRE, MRSA), behavioral care contracts, narcotic agreement contracts, and NPO status >72
hours.

CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE

54

Recruiting participants
After obtaining Institutional Review Board (IRB) approval, retrospective data were
collected from a convenience sample of 100 previous patients meeting eligibility criteria. These
data were supplied by the infection prevention team at the project implementation site in a deidentified form, so the IRB waived the need to obtain informed consent from participants in the
retrospective sample.
The prospective sample was recruited using a sentinel event reporting system within the
electronic health record that identified all positive C. difficile stool assays during the postimplementation period. The principal investigator or research assistant approached each patient
meeting inclusion criteria to explain the purpose, potential risk, potential benefit, and procedures
of the study, and to invite eligible and interested patients to enroll in the study.
Data Collection
Retrospective and prospective data included: participant demographic information,
where the patient was admitted from, nursing unit, primary team, consulting team, risk factors
for CDI, disease severity, clinician guideline adherence, order set adherence (postimplementation group only), clinical cure rate, discharge location, 30- day disease recurrence,
and 30-day readmission rate for CDI. Retrospective data were collected for participants
admitted between April 2015 and July 2015, and prospective data were collected from
November 2015 to February 2016. Data for each participant were recorded on hard-copy case
report forms and promptly entered into a password-protected spread sheet database that was
only accessible by the principal investigator and faculty advisor.
Analysis
The full data analysis plan is described in Table 3.1. Briefly, characteristics of the
retrospective and prospective samples were analyzed using descriptive statistics (mean and
standard deviation for age in years, percent in each category for all categorical variables) and
compared using Student’s t-test for age in years and either the Chi-square test of independence
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or Fisher’s exact test for categorical variables. The level of significance for comparing these
sample characteristics was set at 0.05.
Retrospective and prospective data were pooled to answer the primary PICOT question
for this project. The primary project outcomes (i.e. cure rate, 30-day recurrence of CDI, 30-day
readmission for CDI) were compared between those with complete treatment adherence to
those with incomplete treatment adherence using either the chi-square test of independence or
Fisher’s exact test with a level of significance equal to 0.05.
Table 3.1
Data Analysis Plan
Variables
Age (years)

Statistical analysis
mean, standard deviation
t-test for baseline-to-post comparisons

Sex

% male, % female
Chi-square test for baseline-to-post
comparisons

Race

% White, % African-American, % American
Indian or Alaskan Native, % Asian, % Native
Hawaiian or Pacific Islander, % Other, % Not
identified
Fisher’s exact test for baseline-to-post
comparisons

Location prior to admission

% clinic, % home, % emergency department,
% another hospital, % short term
rehab/extended care facility, % deceased, %
other

CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE

56

Fisher’s exact test for baseline-to-post
comparisons
Primary medical team

% internal medicine, % bone marrow
transplant, % general surgery, % transplant
surgery, % hepatology, %urology,
% pulmonary, % plastic surgery,
% hematology/oncology, % renal transplant
Fisher’s exact test for baseline-to-post
comparisons

Consulting team and effect on clinical cure

% infectious disease, % gastroenterology, %

rate, 30-day recurrence, and 30-day

both

readmission for CDI

Fisher’s exact test for baseline-to-post
comparisons

Disease severity

% mild to moderate, % severe, %
severe/complicated, % unknown, recurrent
mild to moderate, % recurrent severe or %
severe/complicated, % second recurrence,
third or more recurrence
Fisher’s exact test for baseline-to-post
comparisons

Risk factors for CDI

% immunosuppression, % antimicrobial
therapy, % healthcare facility,
% gastric acid suppression, % history of CDI
Chi-square test for baseline-to-post
comparisons
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% yes, % no (orders must have been adherent
to current clinical guidelines)
Chi-square test for baseline-to-post
comparisons

Clinician order set use

% yes, % no
Fisher’s exact test for post-implementation
analysis

Over treatment

% yes, % no

Under treatment

%yes, % no
Chi-square test for baseline-to-post
comparisons

Clinical cure prior to discharge (resolution of
diarrhea and no longer requiring treatment
for CDI)

% yes, % no
Chi-square test for baseline-to-post
comparisons

30-day readmission for CDI

% yes, % no
Chi-square test for baseline-to-post
comparisons

Effect of clinician guideline adherence on
clinical cure rate

Chi-square test of independence for
comparison between adherent and nonadherent groups

Effect of clinician guideline adherence on
30-day disease recurrence

Fisher’s exact test
for comparison between adherent and nonadherent groups

Effect of clinician guideline adherence on
30- day readmissions for CDI

Fisher’s exact test for comparison between
adherent and non-adherent groups
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Protection of Human Subjects
Prior to seeking IRB approval to conduct the study, a required computer-based course
on protecting human subjects was completed by the PI. IRB approval was received from
Valparaiso University. The clinical agency IRB policy required students not associated with their
university affiliate to obtain IRB only from their affiliated university. However, the proposed study
was presented to the academic center’s nursing research committee. Informed consent was
obtained from each participant or from a legally authorized representative. If informed consent
was obtained from a legal representative, a legal documentation stating the right serve as the
legal representative of the participant was obtained and kept with the informed consent. Once
data collection began, the patient health information was stored in a locked filing cabinet
accessible only to the primary investigator. Any computer based records were password
protected to ensure privacy of the subjects. Due to the number of participants to consent, IRB
approval was made to include the utilization of research assistants to obtain consent was
requested and granted.
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CHAPTER 4
FINDINGS
The purpose of this evidence-based project was to determine the effect of adherence to
an evidence-based CDI treatment order set on clinical cure rates, 30-day disease recurrence,
and 30-day readmissions for CDI. A computer-based order set for CDI treatment was developed
and implemented for clinician utilization. The aim was to determine if clinician adherence
improved patient outcomes.
Size
Baseline data were collected from a pre-implementation group consisting of a
convenience sample of 100 inpatient adults diagnosed with stool assay confirmed CDI at a
Midwestern academic center from April 2015 to July 2015 (n = 100). Post-implementation data
was gathered from a convenience sample of 47 (n = 47) at the same academic medical center
from November 2015 to February 2015. Two patients were still hospitalized at the end of the
study period and therefore were excluded from the post-implementation group leaving a postimplementation sample of 45 (n = 45).
Characteristics
Age, gender, race, length of stay, location prior to admission, and disease severity did
not differ significantly between the retrospective and prospective samples. Risk factors for the
development of CDI were also similar between the pre- and post-implementation groups with
exception of antimicrobial therapy (60% vs. 77.8%, p = 0.037) and recent healthcare facility stay
(17% vs. 40%, p = 0.003). See Table 4.1.
Twenty-two percent of participants in the retrospective sample experienced clinical cure,
compared to eight percent in the prospective sample. This difference was not statistically
significant (p = 0.562). There was also a statistically nonsignificant difference between the
retrospective and prospective samples with regard to CDI recurrence or CDI re-admissions (p =
0.425 and 0.096, respectively).
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The effect of gastroenterology and infectious disease consultation on outcomes was also
analyzed. The highest level of adherence was observed when either the gastroenterology or
infectious disease service was consulted (50%). If neither of these services were consulted,
adherence was 36.5%. If both of these services were consulted, adherence was only 25%.
However, these differences were not statistically significant (p = 0.434). There was also not
enough evidence to conclude that the clinical cure rate was better when consulting
gastroenterology or infectious disease specialists (p = 0.504). The 30-day recurrence rate was
21.4% when consulting gastroenterology and 8.3% rate when consulting infectious disease.
When consulting both, the recurrence rate was 25%, and when consulting neither, the
recurrence rate was 11.9%. There was not enough evidence to conclude consulting either team
improved recurrence rates (p = 0.628). There were only five 30 day readmissions for CDI;
therefore, the effect of consultation could not be answered with any confidence.
Table 4.1
Characteristics of Pre- and Post-Implementation Groups

Characteristics

Pre-implementation
(n = 100)

Post-implementation
(n = 45)

p

Age (years) a

54.8 (16.1)

53.2 (16.8)

0.594

Gender (%)b
Male
Female

53 (53.0)
47 (47.0)

25 (55.6)
20 (44.4)

0.775

Race (%)c
Black
White
Hispanic
Unknown

16 (16.0)
82 (82.0)
1 (1.0)
1 (1.0)

8 (17.8)
36 (80.0)
1 (2.2)
0 (0.0)

Length of stay (days) d

7 (4-19)

1 (6-21)

Admitted from (%)c
Clinic
Home
Emergency department
Other hospital
Short/long term care
Unknown

11 (11.0)
32 (32.0)
13 (13.0)
32 (32.0)
3 (3.0)
9 (9.0)

4 (8.9)
10 (22.2)
5 (11.1)
23 (51.1)
0 (0.0)
3 (6.7)

0.824

0.155

0.399
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Risks (%)b
Immunosuppression
Antimicrobial use
Recent healthcare facility
Gastric acid suppression
History of CDI

53 (53.0)
60 (60.0)
17 (17.0)
75 (75.0)
28 (28.0)

29 (64.4)
35 (77.8)
18 (40.0)
36 (80.0)
10 (22.2)

Disease severity (%)c
Mild to moderate
Severe
Severe/complicated
1st recurrence mild to moderate
1st recurrence severe
2nd recurrence
3rd or more recurrence
Asymptomatic

35 (35.0)
13 (13.0)
23 (23.0)
3 (3.0)
8 (8.0)
6 (6.0)
12 (12.0)
0 (0.0)

22 (48.9)
4 (8.9)
11 (24.4)
2 (4.4)
1 (2.2)
0 (0)
4 (8.9)
1 (2.2)

0.198
0.037
0.003
0.511
0.464
0.271

aReported

as mean (SD), p-value from two-sample t test.
as count (%), p-value from chi-square test.
cReported as count (%), p-value from Fisher’s exact test.
dReported as mean, p-value from Wilcoxon sum test
bReported

Clinician characteristics
Pre- and post-implementation characteristics of the primary and consulting teams were
similar. See Table 4.2.
Table 4.2
Pre- and Post-Implementation Clinicians

Primary team (%)c
Internal medicine
Bone marrow transplant
General surgery
Transplant surgery
Hepatology
Urology
Pulmonary
Hematology/oncology
Renal transplant
Plastic surgery

38 (38.0)
7 (7.0)
10 (10.0)
11 (11.0)
4 (4.0)
10 (10.0)
1 (1.0)
11 (11.0)
6 (6.0)
2 (2.0)

17 (37.8)
3 (6.7)
4 (8.9)
6 (13.3)
5 (11.1)
3 (6.7)
2 (4.4)
2 (4.4)
3 (6.7)
0 (0.0)

Consultants (%)c
Gastroenterology
Infectious disease
Both
Neither

19 (19.0)
8 (8.0)
4 (4.0)
69 (69.0)

9 (20.0)
4 (8.9)
0 (0.0)
32 (71.1)

aReported

0.657

0.705

as mean (SD), p-value from two-sample t test.
as count (%), p-value from chi-square test.
cReported as count (%), p-value from Fisher’s exact test.
dReported as mean, p-value from Wilcoxon sum test
bReported
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Treatment measures
A Chi-square test and the Fisher’s exact test were used to determine the effect
evidence-based guideline treatment order adherence on clinical cure rates, 30-day recurrence
rates, and 30- day readmissions for CDI in the pre- and post-implementation groups.
Outcomes
The overall rate of guideline adherence was 39.3% (pre- vs post-: 35% vs 48.9%, p =
0.113). When guideline adherence was not met, 17.9% (pre- vs post-: 18 vs 17.8%) was overtreatment and 41.4% (pre- vs post-: 45% vs 33.3%) was under treatment. The effect of guideline
adherence on achievement of clinical cure rate (resolution of diarrhea and no longer requiring
treatment) was 15.8% adherent group vs 23.9% non-adherent (p = 0.241). The effect of
guideline adherence on 30-day recurrence rates was 12.3% adherent group vs 14.8% nonadherent group (p = 0.425).The effect of guideline adherence on 30-day readmission rates was
7.0% among the guideline adherent group versus 1.1% among the non-adherent group (p =
0.078).
Table 4.3
Treatment Guideline Adherence

Adherent
Frequency
Percent
Row Percent
Collective percent

Over treatment

Under treatment

None

Total

Pre-

35
24.14
35.00
61.40

18
12.41
18.00
69.23

45
31.03
45.00
75.00

2
1.38
2.00
100.00

100
68.97

Post-

22
15.17
48.99
38.60

8
5.52
17.78
30.77

15
10.34
33.33
25.00

0
0.00
0.00
0.00

45
31.03

Total

57
39.31

26
17.93

60
41.38

2
1.38

145
100.00
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Table 4.4
Guideline Adherence Effect on Clinical Cure Rate

Adherence

Frequency
Percent
Row Percent
Collective percent

Clinical cure
Yes

No

Unknown

Not applicable

Total

Yes

9
6.21
15.79
30.00

47
32.41
82.46
45.19

1
0.69
1.75
25.00

0
0.00
0.00
0.00

57
39.31

No

21
14.48
23.86
70.00

57
39.31
64.77
54.81

3
2.07
3.41
75.00

7
4.83
7.95
100.00

88
60.69

Total

30
20.69

104
71.72

4
2.76

7
4.83

145
100.00

Yes

No

Deceased

Yes

7
4.83
12.28
35.00

47
32.41
82.46
38.84

3
2.07
5.26
75.00

57
39.31

No

13
8.97
14.77
65.00

74
51.03
84.09
61.16

1
0.69
1.14
25.00

88
60.69

20
13.79

121
83.45

4
2.76

145
100.00

Table 4.5
Guideline Adherence Effect on 30-day Recurrence Rates

Adherence

Frequency
Percent
Row Percent
Collective percent

Total

Recurrence
Total
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Table 4.6
Guideline Adherence Effect on 30-day Readmission for CDI

Adherence

Frequency
Percent
Row Percent
Collective percent

30-day readmission for CDI
Yes

No

Total

Yes

4
2.76
7.02
80.00

53
36.55
92.98
37.86

57
39.31

No

1
0.69
1.14
20.00

87
60.00
98.86
62.14

88
60.69

Total

5
3.45

140
96.55

145
100.00
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CHAPTER 5
DISCUSSION
The purpose of this evidence-based project was to determine the effect of clinician
adherence to Clostridium difficile infection treatment guidelines on clinical cure rates, 30-day
disease recurrence, and 30-day readmissions for CDI. The following section includes a
discussion of the findings, applicability of the theoretical and evidence-based practice
framework, study strengths and weakness, and clinical implications.
Explanation of findings
Adherence to the CDI severity-based treatment guidelines did not significantly improve
clinical cure rates, 30-day recurrence rates, or 30-day readmission rates for CDI. In fact, the
clinical cure rate and 30-day readmission rates for CDI tended to be worse in those with
complete guideline adherence. Because these results were not statistically significant, they
could have occurred due to chance alone. However, these paradoxical findings require further
investigation to explore factors that could be useful in predicting which patients will benefit from
guideline adherence and which ones may not. One way to approach this would be to collaborate
with a nurse scientist and/or biostatistician to develop regression models that can be used to
explore the effects of various predictors, including interaction effects, on each outcome. While
this approach is beyond the scope of this project, another approach may be to collaborate with
clinicians or use clinical experience to identify variables that may have had an impact on the
outcomes of interest.
Forty-five of the eighty-five of CDI cases were included in the prospective sample. Forty
patients were not included for various reasons. Twenty-one patients were discharged prior to
the investigator being able to obtain IRB required written consent for participation. The principal
investigator (PI) was at the academic medical center three days a week. Therefore, there were
several patients discharged prior to the PI returning to the academic medical center resulting in
missed recruitment opportunities. Two patients were excluded from the study as they were still
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hospitalized at the time the study ended. Therefore, data on clinical cure, 30-day recurrence,
and 30-day readmission rates could not be obtained in those two cases. To reduce the number
of lost recruitment opportunities three research assistants (2 nurse practitioners and 1
physician) were added after IRB approval was received. Two cases were disease recurrence
readmissions and were ineligible due to previous recruitment. Ten patients had some degree of
altered mental status making informed consent unattainable. Two were intensive care patients
and therefore were excluded due to failure to meet eligibility criteria. Two patients refused
participation. One patient refused participation citing previous participation in multiple studies
and several recent hospitalizations. The other patient was not able to fully comprehend the
purpose of the study and his family declined participation on his behalf. One patient had a
positive C. difficile stool assay without symptoms and was considered colonized. In the postimplementation group, 47% of patients that were diagnosed with CDI were not included in the
study. Patients that were not consented due to altered mental status, may have more severe
presentations of this disease. On the other hand, some of the patients that were discharged
prior to being consented may have had shorter length of stays and less severe disease.
Therefore, the post-implementation sample (n = 45) may not have been a true representation of
the patients diagnosed with CDI at the clinical agency during the post-implementation period.
Treatment variability and experience of the prescribers may also have accounted for
outcome differences. At the academic medical center, residents and fellows begin new rotations
in July. Post-implementation data were collected after a new group of residents started rotations
as opposed to the retrospective sample that received care from more experienced medical
residents and fellows. Therefore, the prospective sample may have received less treatment
from less experience clinicians.
There also may have been a greater number of patients with post-discharge follow up
outside of the academic medical center health care system. Since the clinical agency is a
tertiary care center it is common for patients to receive post-discharge care at other health care

CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE

67

systems. Therefore, there may have been unaccounted for cases of disease recurrence and/or
readmission for CDI.
There also may have been confounding factors between the pre- and postimplementation groups that results in outcome variability. Those factors may have included comorbidities, acuity levels, re-admissions to other hospitals, patient noncompliance nonadherence with treatment, and failure to correctly use appropriate CDI transmission-based
precautions. Since participants were not randomly assigned to either the “adherent” or “nonadherent” groups, and these variables were not measured in this project, it cannot be assumed
or verified that the confounding factors listed above were evenly distributed between participant
groups.
An additional explanation for outcome variability may have been in the informatics
design of the order set. Other computer-based order sets at the clinical agency leave all of the
order options visible once a treatment option has been selected and initiated. For example, if a
clinician selected metronidazole 500 mg orally three times a day for ten days under the mild to
moderate disease recommendations, then all of the other treatment options would no longer be
visible. If the patient did not respond to the initial treatment with 5 to 7 days or if the patient
development a higher disease severity from initial presentation it would have been appropriate
to escalate the treatment. However, those other treatment options would no longer have been
visible to the clinician without initiating a new CDI order set. With the CDI order set, once a
treatment option is selected all the other options “drop off” and are no longer visible. Therefore,
clinicians who used the order set were unable to use the same order set to modify the CDI
treatment plan. They would have had to initiate a new CDI order set for the patient if the disease
severity changed, which is not how order sets are traditionally used in the implementation site.
This may have hindered clinicians escalating treatment in participants who did not respond to
the initial treatment or for those patients that developed a worsening severity of disease.
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The results of this study varied from previous studies examining the effect of guideline
adherence on patient outcomes that identified a statistically significant positive effect of clinician
guideline adherence on patient outcomes. One retrospective study at a 420 bed tertiary care
center examined the effect of treatment variation on the development of CDI related
complications including recurrence, any surgical procedure to cure CDI, toxic megacolon, and
30-day mortality (Brown & Seifert, 2014). Length of stay and achievement of clinical cure rates
were also examined. Only 51.7% of prescribers were followed the 2010 SHEA/IDSA treatment
guidelines (Brown & Seifert, 2014). The patients who received guideline-adherent treatment had
fewer complications than those patients who received guideline non-adherent treatment (17.2%
vs 56.3%, p = <.0012) (Brown & Seifert, 2014). The difference was mainly due to a reduction in
mortality (5.4% vs 21.8%, p = .0012) and infection recurrence (14% vs 35.6%, p = .007) (Brown
& Seifert, 2014). Patients who presented with severe and severe complicated disease received
guideline adherent treatment significantly less often than with mild disease which was consistent
with the findings of this EBP study (Brown & Seifert, 2014). Study design may account for some
of the outcome difference. This study was retrospective, had a larger sample (n = 180), included
intensive care patients, and a more diverse racial composition that may or may not account for
outcome differences. There were also no cases of CDI related mortality in this study that may
have impacted outcome differences. The investigators acknowledged that there may have been
unaccounted for treatment failures as there were no formal follow ups with patients upon
discharge (Brown & Seifert, 2014).
Three identified studies examining the effect of guideline adherent treatment on patient
outcomes all demonstrated a significant rate of clinician non-adherence which was consistent
with this study. The three studies had pre-intervention guideline non-adherence rates ranging
from 51.7% to 89.0% (Brown & Seifert, 2014; Jardin et al., 2013; Mc Ellistrom et al., 2014).
Another study demonstrated improvement in refractory disease after implementation of a
severity-based treatment policy (37 % to 15%, p = 0.035) (Jardin, et al., 2013). Again, the
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sample size was larger (n = 144). Additionally, the outcome difference may have been related to
the mandatory nature of the treatment policy change. Utilization of the guideline- adherent order
set in this study was voluntary for clinicians.
Theoretical framework
The epidemiological triangle was the theoretical framework used to illustrate the
interaction of the key components of communicable diseases, in this case Clostridium difficile
infections. The components as it applied to the study included: Clostridium difficile (the
infectious agent), patient (the host), and the academic medical center (the environment).
Preventing and treating CDI is dependent upon understanding the components of epidemiology
including pathogenicity, sporulation, transmission, and impact of the bacterial toxins on the
gastrointestional tract will continue to be important factors in treating CDI, preventing associated
complications, preventing transmission, and reducing disease recurrence. The order set
contained treatment targeted at eliminating Clostridium difficile bacteria causing an infection
based upon disease severity. The intent of the order set was to influence and guide clinicians to
use evidence-based treatment. Identifying risk factors for the development of CDI assisted the
clinicians in eliminating or reducing modifiable risks factors when feasible. For example,
reducing or eliminating gastric acid suppression use. However, factors such as age could not be
modified. Additionally, the order set prompted the utilization of enteric precautions. This
intervention was aimed at reducing person-to person transmission through the use of protective
wear (gowns and gloves), proper handwashing with soap and water, and dedicated equipment
(disposable thermometer and stethoscope). Once enteric precautions were initiated, a sign was
placed on the patient hospital door to alert persons entering the room of the guidelines to be
followed before, during and after entry. The framework also helped to understand the effect of
treatment on the host or outcomes such as cure, recurrence, and treatment failures. Although
the framework provides a basic understanding of communicable diseases and interactions with
the environment and host, it is not specific to CDI. Despite the applicability of the framework, it
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was lacking generalizability as each infectious agent, host, and environment has unique
features that cannot be accounted for by the epidemiological triangle.
Evidence-Based Practice Framework
The Iowa Model Revised: Evidence-Based Practice to Promote Excellence in Health
Care was the evidence-based practice framework used to guide the development of this study.
The framework was an effective model as its steps of the algorithm correlated with the process
necessary to implement a practice change at the clinical agency. The model was modified as
several obstacles during the change implementation required revision or involvement of other
clinical agency stakeholders that were not previously identified. The clinical agency also
required order set revisions to comply with institutional policies. An example was the inclusion of
fidaxomicin on the initially proposed order set under disease recurrence. The request to include
it on the order set was declined due to clinical agency policy against the use of non-formulary
medications, such as fidaxomicin, on order sets. A suggestion was made to add a statement to
the order set advising the users of the non-formulary medication status and requirement for an
infectious disease consultation to order this particular medication. Unfortunately, making this
addition to the order set was rejected. It was felt that this would potentially increase unwarranted
use of this costly medication. It is unlikely that modifications to the model would be required for
future use as they were primarily necessary due to the investigator’s lack of familiarity of the
clinical agency process to implement practice changes. However, the model can easily be
adapted to meet the need of the user.
Strengths and weaknesses
The study incorporated current evidence from literature and included a multidisciplinary
team for order set development, content review, and implementation. The order set is an easily
accessible, disease-severity based treatment tool for clinicians. Although previous studies have
implemented treatment stewardships, use of an order set was a novel approach to CDI
treatment at the clinical agency. As far as it is known, an order set specifically directed at CDI
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treatment had not previously been developed or implemented at the clinical agency. Despite the
availability of the order set, only 13% of clinicians utilized the order set. This could be potentially
explained by several factors including: lack of order set awareness, clinician confidence in
personal CDI treatment knowledge, avoidance due to belief that order sets do not allow for
treatment individualization, lack of awareness of clinical agency treatment variability among
clinicians, and non-mandatory use status. Although multimodal education was used prior to
order set release, the education period was limited to two weeks prior to the start of the
implementation period due to delays in final approval of the order set. A longer education
period prior to the order set release may have proven beneficial as it would allowed for more
opportunities to reach out to more clinicians and medical students. The multimodal educational
approach included: email notifications to department chiefs and chief residents, medical
newsletter notification, information technology newsletter notification, posters, and face-to-face
education. In retrospect, sending out email notifications to all clinicians and medical students
would have been a better choice to ensure more clinicians and medical students received
personal notification of the order set release. In person in-services or computer-based
presentations prior to the order set release may have been useful for increasing clinician
awareness to the increased number of cases of CDI at the academic medical center over the
last three years, clinician treatment variability, upcoming financial penalty changes for hospital
acquired CDI, and the possible association between guideline non-adherent treatment and poor
patient outcomes. Short questionnaires could have also been used to test clinician knowledge of
current CDI treatment guidelines and assist in the recognition of any knowledge deficits related
to CDI treatment. Initially a computer-based message alerting clinicians of a positive stool study
and a reminder to utilize the order set was suggested. Permission to implement such a
message was declined to due to concern about alert fatigue.
Another limitation may have included avoidance of order set use among some clinicians
as they may feel it fails to address the need to individualize treatment in special cases. This
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issue was brought forth by one of the key stakeholders. However, as with every order set at the
clinical agency a written disclaimer states that the recommendations in the order set serve as a
guide and are not to replace clinical judgement. Additionally, the orders could be easily modified
by clinicians. For example, a longer treatment period can be changed to meet the needs of
individualize patients. One of the above mentioned studies successfully implemented a policy
change that directed clinicians to utilize guidelines for treatment. The study demonstrated
positive patient outcomes associated with guideline adherence. Given the initial stakeholder
resistance to voluntary utilization of a guideline-based order set, significant resistance would
probably make a mandatory policy change unlikely.
Generalizability to patients outside of the clinical agency was also a possible limitation
as the patient population at the academic medical center have numerous risk factors for CDI
(i.e. immunosuppression, antimicrobial use, recent health care facility stay, gastric acid
suppression, and history of CDI) that may not be seen to the same extent in smaller hospitals.
Despite the identified limitations, this study enforced there are improvements to be made
both in the treatment and prevention of CDI. This study has brought attention to the need for the
clinical agency and stakeholders to strengthen efforts to improvement strategies directed at both
prevention and treatment.
Implications for the future
Practice. In response to the growing number of HAI, a government-based program was
established to reduce payments to hospitals with poor HAI prevention performance. Currently,
CAUTI, CLABSI, and surgical site infections (colon and abdominal hysterectomy) are quality
measures tracked under the program. In 2017, MRSA and CDI will be added to the list of quality
measures. Health care systems that fail to respond to the growing number of CDI will be at risk
for financial penalties and reduced reimbursement. Reducing risk factors associated with CDI
has proven challenging. Those risk factors include immunosuppression, antimicrobial therapy,
recent health care facility stay, gastric acid suppression, and history of CDI. Although the
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purpose of this study focused on treatment, implementing preventive measures will also be
instrumental in reducing the incidence of CDI. Treatment goals need to be aimed at using
evidence-based practices to successfully treat CDI and reduce future recurrence. Postimplementation data indicated few clinicians are using recommended treatment for CDI,
especially for severe and severe complicated disease. These more severe cases may develop
potentially fatal complications, such as pseudomembranous colitis or sepsis. Dissemination of
the findings can be utilized to encourage incorporation of current evidence into clinical practice.
It has also been demonstrated that preventive efforts such as reducing modifiable risk factors
(i.e. gastric acid suppression and antimicrobial therapy) may potentially reduce disease
recurrence. Implementing a treatment policy as with one of the previously mentioned studies
would likely improve clinician guideline adherence. The findings will be disseminated at the
clinical agency to determine if the set will be extended beyond the pilot study period. It will also
be suggested for the clinical agency to develop a multidisciplinary team aimed at both treatment
and prevention strategies.
Theory. Utilization of theoretical framework, such as the Iowa Model, will prove
invaluable for future efforts in the prevention and treatment of CDI. The model offers a
systematic approach to identifying problems, prioritizing problems, searching for and
synthesizing best evidence in literature, developing and implementing changes, evaluating
implemented practice change, and determining if the proposed change will be adopted into
practice. The model has been revised twice times since the original model was released. The
changes have been in response to changes in the health care industry and used feedback. This
demonstrates the responsiveness and adaptability to the dynamic nature of health care. It is
likely the model will continued to be revised in response to changes in healthcare.
Research. Future longitudinal, multicenter studies should be conducted to determine the
long-term effect of treatment stewardships on clinical cure rates, 30-day disease recurrence,
and 30-day readmission rates for CDI. Future studies should also be designed to account for
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confounding factors that may impact patient outcomes. Future studies should also consider
follow-up patient phone calls to determine a more accurate account of disease recurrences and
readmissions. As previously mentioned, there were patients transferred from other hospitals for
their treatment. Post discharge care may have been at local health care systems limiting an
accurate accounts of disease recurrence and 30-day readmissions for CDI.
If the order set is adopted into practice at the clinical agency, efforts must be made to
conduct interval literature reviews to identify any new evidence related to CDI treatment and
determine if it should be incorporated in order to reflect best practice.
Education. Although patient education was not an intended focus of this study, only
20% of patients in both the pre- and post-implementation groups received CDI-specific
discharge instructions. In the post-implementation group, the failure to provide CDI specific
instructions did not appear to have a negative effect on 30-day disease recurrence (22.2%
received instructions vs 5.6% did not receive instructions, p = 0.173) or 30-day readmission
rates (22.2% received instructions vs 8.3% did not receive instructions, p = 0.258). Failure to
provide CDI specific discharge instructions (i.e. risk factors, transmission, and hand washing) to
patients and their families may contribute to disease recurrence and transmission to others
although this study did not demonstrate any negative effect on patient outcomes. An
explanation for this finding may have been clinician failure to document CDI specific instructions
provided at the time of discharge. Additionally, clinician education regarding CDI treatment must
be continued, as well as the potential impact of inappropriate treatment of CDI. This includes
complications associated with CDI and the potential financial impact on healthcare systems for
hospital-acquired CDI.
The study has showed a significant number of patients did not receive guideline
adherent treatment. The long term implications on patient outcomes has yet to be fully
demonstrated. Treating patients with a mild to moderate disease may lead to unnecessary
utilization of vancomycin and increased risk for development of vancomycin resistant
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enterococcus (VRE). Unwarranted use of vancomycin also creates an unnecessary expense as
the cost is higher than metronidazole. Additionally, patients with severe or severe/complicated
disease may develop CDI related complications (i.e. pseudomembranous colitis) due to failure
to appropriately treat with a combination of metronidazole and an appropriate dose of
vancomycin. Inclusion of fidaxomicin for recurrent disease may have also reduced the number
of recurrences. Despite the cost of fidaxomicin and its non-formulary status at the clinical
agency, utilization may have decreased recurrence and proven less costly than the expense
and potential complications associated with disease recurrence, as well as the possible need for
the potentially more costly treatment option, fecal microbiota transplant.
Conclusions
CDI is a continued health care issue that can result in a number of disease-associated
complications. Successfully reducing the incidence of CDI must include interventions aimed at
both prevention and treatment. This study has demonstrated there is still work to be done in
making improvements to both preventing and treating this growing problem. In addition to the
possible physical complications associated with CDI, there may also be a significant financial
impact on healthcare systems. It has previously been demonstrated that CDI has been
associated with increased length of stay (LOS). In addition, impending reimbursement changes
for HAI may have a potentially devastating effect on health care systems as CDI will be added
the list of HAI that will result in potential financial penalties beginning in 2017. Efforts aimed at
disease prevention, such as enteric isolation precautions for suspected and confirmed CDI
cases, responsible use of antibiotic and gastric acid suppression, and patient education should
also be encouraged. Failure to incorporate evidence-based practice for CDI treatment and
prevention may have potentially devastating physical and financial consequences. This study
also demonstrated doctoral-prepared advanced practice nurses have the ability and
commitment to develop, implement, and evaluate clinical practice changes to improve patient
outcomes through incorporation of evidence-based practice. References
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ACRONYM LIST
AAD: antibiotic-associated diarrhea
ACA: Affordable Care Act
ACG: American College of Gastroenterology
AHRQ: Agency for Healthcare Research and Quality
CASP: Critical Appraisal Skills Programme
CDC: Centers for Disease Control and Prevention
CDI: Clostridium difficile infection
CINAHL: Cumulative Index to Nursing and Allied Health
CMS: Centers for Medicare and Medicaid Services
EBP: Evidence-Based Practice
HAC: hospital acquired conditions
HAI: hospital acquired infections
HRRP: Hospital Readmission Reduction Program
IOM: Institute of Medicine
JBI: The Joanna Briggs Search Institute
NCBI: Medline/National Center for Biotechnology Information (NCBI)
PI: principal investigator
SHEA/IDSA: Society of Hospital Epidemiologists of America/ Infectious Disease Society of
America
VRE: vancomycin resistance enterococcus
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Appendix A. Clostridium difficile Infection Order Set

Clostridium difficile Infection
The person initiating entry should write legibly, date the form (using Mo / Day / Yr), enter time, sign,
and indicate their title.
Until signed, these are for general information and reference only. They should not be relied on as advice for a particular patient or situation or as a
substitute for the independent professional judgment of the physician.

Date

Time

Physician Orders
Labs
serum creatinine daily collection routine, results routine x 2 days
serum albumin daily collection routine, results routine x 2 days
CBC with differential daily collection routine, results routine x 2 days
venous lactate x 1 collection routine, results routine
Medications
**Discontinue inciting antibiotics if possible
**Discontinue or limit gastric suppressant medications (i.e. H2 blockers, PPIs) if
possible

**Duration can be modified by the clinician to individualize treatment
Mild to Moderate Disease
**WBC count less than 15,000 OR serum creatinine less than 1.5 times baseline
AND absence of severe disease criteria
metroNIDAZOLE 500 mg Q8H for 10 days
PO (DEF)
Feeding Tube
**For ALLERGY / intolerance to metroNIDAZOLE OR
No clinical improvement in 5-7 days on metroNIDAZOLE OR
Pregnant / breastfeeding OR
History of inflammatory bowel disease
vancomycin 125 mg Q6H, oral susp. for 10 days
PO (DEF)
Feeding Tube
Severe Disease
**Serum albumin less than 3 gm/dL AND one of the following: serum creatinine
greater than 1.5 times baseline OR abdominal tenderness OR WBC greater than or
equal to 15,000
vancomycin 125 mg orally Q6H for 10 days
PO (DEF)
Feeding Tube
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Severe Complicated Disease
**Intensive care unit admission for Clostridium difficile infection OR hypotension with or
without required vasopressors OR fever greater than or equal to 38.5 OR ileus OR
megacolon OR significant abdominal distention OR mental status changes OR WBC
greater than or equal to 35,000 OR WBC less than or equal to 2,000 OR serum lactate
greater than 2.2 OR evidence of end organ damage

vancomycin 500 mg Q6H for 10 days
PO (DEF)
Feeding Tube
AND
metroNIDAZOLE 500 mg IVPB Q8H for 10 days
AND
*IF ILEUS is present or suspected OR if there is a history of Hartman’s pouch,
ileostomy, or colon diversion.
vancomycin 500 mg in 500 mL 0.9% sodium chloride per rectum Q6H
**Consider surgical consultation for all severe complicated cases
Recurrent Infection Treatment
**Recurrence defined as an episode that occurs 8 weeks after a previous episode that
involved resolution of symptoms
First Recurrence of mild to moderate disease: Repeat initial regimen
metroNIDAZOLE 500 mg orally Q8H for 10 days
PO (DEF)
Feeding Tube
OR
vancomycin 125 mg Q6H for 10 days
PO (DEF)

Feeding Tube

First Recurrence of severe or severe complicated disease
vancomycin 125 mg Q6H for 10 days
PO (DEF)
Feeding Tube
Second Recurrence
vancomycin 125 mg Q6H for 10 days,
PO (DEF)
Feeding Tube
THEN
vancomycin 125 mg Q12H for 7 days
PO (DEF)
Feeding Tube
THEN
vancomycin 125 mg orally Q24H for 7 days
PO (DEF)
Feeding Tube
THEN
*May choose a duration of up to 2-8 weeks*
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vancomycin 125 mg Q48H for 2 weeks
PO (DEF)
Feeding Tube
***For reoccurrence and treatment failure CONSIDER infectious disease and GI
consultation
Third and Subsequent recurrences
***consider fecal microbiota transplant
Consults
Note: Ordering provider must call service for consult*
medical service consult : gastroenterology
medical service consult : surgical
medical service consult : infectious disease
Social work consult – if vancomycin therapy needed upon discharge

